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ABSTRACT
DETERMINATION OF PANCREATIC AND SALIVARY AMYLASE
BY ENZYME IMMUNOASSAY AND THEIR PREVALENCE
IN HYPERAMYLASEMIC PATIENTS
Sandra Borgens Ward
Old Dominion University, 1994
Director: Dr. James H. Yuan

Currently, amylase determinations are nonspecific for the organ source and are
based entirely on the enzymatic properties of amylase to produce a measurable
product or byproduct. The determination of pancreatic amylase is important in the
diagnosis of acute pancreatitis. Most commercially available tests for amylase employ
the measurement of the change in NADH absorbance at 280 nm or of the
p-nitrophenol released from a maltotetrose substrate. These are nonspecific
measurements of pancreatic amylase and often necessitate other tests to be run such as
a serum lipase.
The two predominant isoenzymes of amylase are pancreatic (p-amylase) and
salivary (s-amylase); the most important of which is pancreatic. Pancreatic amylase to
date is determined by the removal of salivary amylase by monoclonal antibody, wheat
germ, or ion-exchange chromatography. Also amylase isoenzymes are determined by
electrophoresis. These methods are time consuming and lack either specificity or
quantification capability. There is a 1% difference in the amino acid sequences of
pancreatic and salivary amylase. These structural differences between pancreatic and
salivary amylase are small but significant enough that they should enable a
monoclonal antibody to be produced for each isoenzyme.
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A sensitive and specific microwell assay based on sandwich technique for the
quantitative determination of the p-amylase and s-amylase was developed. Microwells
were utilized for the solid-phase immobilization of the amylase inhibitor
cycloheptaamylose (CHA) which was coupled to bovine serum albumin (BSA) by
carbodiimide coupling. Monoclonal antibodies were produced against p-amylase and
s-amylase (PAb and SAb). These were purified by Protein-A affinity chromatography
and then coupled to horseradish peroxidase (HRPO) by carbodiimide coupling. The
microwells which were coated with oxidized CHA-BSA (CHA-BSA) were incubated
with patient’s serum and then allowed to react with the PAb-HRPO and SAb-HRPO.
This EIA method is able to distinguish between p-amylase and s-amylase
quantitatively, rapidly and has the capability for automation. The correlation
coefficients for human serum samples were 0.920 and 0.867 for p-amylase and
s-amylase when comparing this EIA method and protein electrophoresis then staining
for amylase. The limit of detection was determined to be 8 U/L for p-amylase and 16
U/L for s-amylase. The percent coefficient of variation for p-amylase was found to be
7.79% for the normal control and 6.28% for the abnormal control. The percent
coefficient of variation for s-amylase was found to be 9.42% for the normal control
and 9.29% for the abnormal control.
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Chapter I
INTRODUCTION
A. Background
1. Chemical properties amylase
Pancreatic a amylase (a-l,4-glucan 4-glucanohydrolase EC 3.2.1.1) is present
in two equally active forms (I and II). To date, structural studies have been
performed on porcine pancreatic amylase. Its molecular weight has been calculated to
be 54,967.12 It is also not significantly glycosylated.1 Porcine pancreatic a-amylase
consists of three domains. The N-terminus contains: domain A, the largest portion,
and domain B. Domain A folds into a typical (alpha/beta)8 barrel structure. Between
the third beta-strand and the third helix of domain A lies domain B. This region has
two antiparallel beta-sheets and a long loop, whose internal structure is not as regular.
Domain B is involved in substrate binding.3 Binding studies indicate that there are two
binding sites: one in a deep cleft that exists 3 nm from the carboxyl end of the
alpha/beta barrel, which is believed to be the active site; the other binding site is
believed to be on the surface of the molecule about 2 nm away from the active site
region.4 A globular C domain exists in the C-terminal region. It consists of a chain
folded into an 8-stranded antiparallel beta-barrel.
A calcium ion appears to form an ionic bridge between domain A and B.3 The
attachment of the calcium ion is essential for the structural integrity of amylase.
Calcium ions can be replaced by strontium or barium ions. Chloride ions are known
to be required for amylase activity.4,5 Chloride’s attachment is at the center of the

1
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alpha/beta barrel and is bound to a specific lys residue. Chloride can be replaced by a
bromide ion.6
Robyt and French studied the binding sites of maltotriose (G3) through
maltooctaose (G8) with the use of 14C label in the reducing glucose unit. Maltodextrin
G3 was cleaved at bond one and two from the reducing end with the highest
frequency at bond one. As the length increased to G4, bonds one and two were still
cleaved; however, the highest frequency became bond two. Cleavage of maltodextrins
G5 through G7 remained at bond 2; however, the maximum cleavage shifted with G8
to bond 3.
The active binding site was therefore proposed to bind a maximum of five
glucose units. Also, the binding of the substrate appeared to be polar with the
reducing end to the right of the catalytic groups. With G5 and higher
oligosaccharides, the cleavage was explained by the tendency of the molecule to
occupy as fully as possible the entire binding site; thus, the ends overlap, and
cleavage was at the number three bond. This was supported by the fact that G5 was
resistant to cleavage of all bonds except number two.
As the concentration of the substrates increased, the products shifted. The data
supported the fact thaf at low concentrations of G3 the products are due to hydrolysis
since G1 was produced at a faster rate than G2. At high concentrations, G2 was
formed at a faster rate. This supports the hypothesis that the products are the result of
condensation of two G3 molecules to produce a G6, which subsequently undergoes
hydrolysis to give three G2’s.
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Maltodextrin G4 demonstrates a concentration dependence of the product
distribution; however, the results are not as easily interpreted. The most reasonable
explanation was still that a condensation reaction takes place initially,’ and then
hydrolysis takes place. The frequency of cleavage suggested that the most stable
binding favors formation with cleavage at bond three.7
There is a 7% difference in the amino acid sequences of the two predominant
isoenzymes, salivary (s-amylase) and pancreatic amylase (p-amylase).8 They also
differ in their activation energies and enthalpy changes.9 Electrophoresis yields the
following isoenzymes of amylase: two pancreatic forms (P, and P2) and sometimes a
third (P3), and two salivary forms (S, and S^).10 P3 is not found in normal pancreatic
tissue but does occur in acute pancreatitis. The most common isoforms found are P2
and S,. On migration on cellulose acetate and agarose S2 migrates closest to the
anode, followed by S,, P3 if present, P2 then P,.u
2. Sources of amylase
Human amylase is found in a variety of sources: pancreas, saliva, serum,
urine, tears, breast milk, sweat, amniotic fluid, ovary, fallopian tubes and testes.1213
The two most concentrated areas of amylase are the salivary glands and the pancreas14
with the following values: parotid 1710 ± 897 U/g, submandibular 605 ± 354 U/g,
and pancreas (258 + 137 U/g).11 Normal pancreatic tissue contains no s-amylase.15
Normal total serum amylase is 25-125 U /L.12
Compared to the pancreas other tissues of the digestive tract contain 1/35 to
1/45 the amount of amylase. The amylase that is present in these tissues is composed
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of 25% p-amylase and 75% s-amylase.15 Values of other tissues contain 1/100 to
1/1000 less amylase as compared to the salivary glands and pancreas. Tissues that
contain more than 90% p-amylase are the pancreas, jejunum, liver, placenta, testis,
skeletal muscle, and spleen. Only the salivary and thyroid contained more than 90%
of the s-amylase. All the other tissues contain mixtures of the two isoenzymes.11
Amylase is eliminated from the body via the glomerulus of the kidney and is
not reabsorbed by the tubules.16Therefore, urinary amylase levels reflect the serum
level since the enzyme is not usually reabsorbed by the tubule except in renal tubular
damage. Toxic compounds like the proteolytic enzymes of pancreatitis and ethanol can
effect not only the pancreas but the renal tubules as well resulting in an elevated
amylase.17

3. Significance
a. Hyperamylasemia
(1)

Acute pancreatitis

At one time hyperamylasemia was believed to be an exclusive indicator of
pancreatic or salivary disease.18The determination of p-amylase is still important in
the diagnosis of acute pancreatitis.19 Causes of acute pancreatitis include obstruction,
vascular disorders, trauma, toxins and a variety of metabolic disorders. The one
common factor of all forms of acute pancreatitis is the increased permeability of the
cell membrane and the autodigestion of the pancreatic proteolytic enzymes.20 Increase
of serum amylase is the result of an increased rate of entry into the circulation and/or
the decreased clearance of this enzyme. Although the pancreas and salivary glands are
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the two sources with the greatest amount of amylase,14conditions other than
pancreatitis and salivary disease have now been attributed to hyperamylasemia: such
as, tumors of the lung, ovary,12and breast;21 intestinal obstruction or inflammation;
common-duct stones; hepatitis; facial or abdominal trauma22; autoimmune diseases;23
chronic alcoholism; postoperative cardiopulmonary bypass; eating disorders; lactic
acidosis; renal failure; macroamylasemia; and total body irradiation.24
In a comprehensive study of 368 patients over a 4 year period, the incidence
of acute pancreatitis revealed: 56% related to gallstones, 16% to alcohol, and 28%
idiopathic.25 A similar study showed slightly different percentages: 55% alcohol
abuse, 27% gallstones, 6% pancreatic cancer, 12% miscellaneous.26 One study in
Scotland showed the most common etiology of pancreatitis to have been biliary tract
disease (30% of the males; 53% of the females). Pancreatitis related to alcohol
occurred in 27% of the males, but in only 3% of the females. The most common
complication was pancreatic pseudocysts, then pancreatic abscesses, renal failure,
respiratory failure, and last disseminated intravascular coagulation.27
Sources of hyperamylasemia in a study by Dougherty showed 32% was due to
gallstones, 49% alcoholic patients, and 19% other. In the gallstone patient group their
amylase levels were significantly higher than the non gallstone groups; also the serum
amylase decreased significantly in 24 hours. On surgery no or little pancreatitis was
found in the gallstone group.28
Certainly the two most common groups are biliary or alcohol related. The
migration of a gallstone causing the blocking of the ampulla of Vater can cause a
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gallstone pancreatitis.29 In some individuals, the ampulla of Vater is shared with the
bile duct. In others it is separate but lies within close proximity.20 This diagnosis can
be made based on history, physical exam and a serum amylase above 1000 IU/L,
ultrasound, and CT scans.29
With the high correlation to alcohol abuse one would think that the reciprocal
would be true: individuals with alcohol abuse have a higher incidence of pancreatic
disease than the normal population. However, in a study of individuals arrested for
drunk driving, it was found that pancreatic enzyme levels were twice normal in only
3/300; whereas, hepatic enzymes were twice normal in 31/300. It was concluded that
there were other factors besides alcohol that predisposed persons to acute pancreatitis
and that the liver is more sensitive to alcohol abuse than the pancreas.30
Pancreatitis first presents itself with the following symptoms (in order of their
prevalence): epigastric pain, localized or generalized tenderness, nausea and vomiting,
fever, palpable mass and ascites.31 Symptoms are similar with the most common
complaint being abdominal pain.32,33 Most helpful in diagnosis was hyperamylasemia;
then elevated amylase/creatinine clearance ratio (C ^/C J.34 Lipase values are also
often included.35 Autopsies over a five year period showed that out of 43 patients
having acute pancreatitis, the disease was first diagnosed at autopsy in 30% of the
cases. The diagnosis could have been present on admission in over half of these.
Alcoholism, biliary tract disease, and surgery around the pancreatic area were among
the most common causes. Abdominal pain was present in only one patient. Amylase
levels were determined in 25% of the cases, but only 10% had amylase values in the
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diagnostic range (equal or greater than three time the upper limit.36 Wilson and Imrie
raised the question why the diagnosis of acute pancreatitis was missed so frequently.
In their review of deaths due to acute pancreatitis over a 10 year period, acute
pancreatitis was not diagnosed until autopsy in 33% of the cases.37 Only 7% had
abdominal pain. The majority, 68%, presented an atypical picture with another known
or suspected condition or were a postoperative result. Amylase determinations were
made in only 9% of the cases. They concluded that non-diagnosis was most often due
to the lack of considering acute pancreatitis as a cause; hence, no diagnostic test that
would reveal acute pancreatitis was performed.37
(2) Predisposed groups
Some groups of individuals have been identified to be predisposed to
hyperamylasemia and/or pancreatitis. In homozygous sickle cell patients, it was found
that 50% had elevated serum amylase values. This seems to suggest that they may be
predisposed to chronic pancreatitis.38
Studies by Prinz have led to the conclusion that whereas infarction can induce
inflammation and necrosis of the pancreas, ischemia may aggravate but does not cause
pancreatitis.39 Also in a study of 52 patients with postoperative pancreatitis, 30 had
previous procedures near the pancreas. The most common procedures were: biliary,
colectomy and intestinal resection.40
(3) Cardiopulmonary bypass
Of particular note is the high incidence of hyperamylasemia and/or pancreatitis
related to cardiopulmonary bypass surgery. In a study of three hundred patients
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undergoing cardiopulmonary bypass, 32% developed hyperamylasemia. Within this
group 58% were asymptomatic and had normal lipase, 33% had subclinical
pancreatitis, and 8% actually had acute pancreatitis. Isoamylase studies indicated that
the hyperamylasemia was not due to p-amylase. Mortality was higher in patients with
hyperamylasemia.41 A study by Chang of 75 patients had similar results.
Hyperamylasemia was seen in 36% of the patients. Of these patients, 3 out of the 27,
developed acute pancreatitis. Analysis of these patients revealed that coronary artery
disease predisposed a patient to post bypass hyperamylasemia. This phenomena has to
be closely monitored since there is such a high incidence of non pancreatic
hyperamylasemia, and yet the possibility of acute pancreatitis existed.42 Some reports
suggest ischemia may be the cause of a greater risk of developing pancreatitis after
undergoing cardiopulmonary bypass, but this has not been proven.43
Evidence that associates the preoperative administration of calcium chloride in
cardiac surgery to have a high correlation with hyperamylasemia has also been
implicated. Fernandez analyzed 300 patients undergoing cardiopulmonary bypass and
reported "pancreatic cellular injury was significantly associated with preoperative
renal insufficiency, valve surgery, postoperative hypotension, and preoperative
administration of calcium chloride. "43The risk of pancreatic cellular injury was also
determined to be dose related to the calcium chloride. Administration of more than
800 mg of calcium chloride per square meter of body-surface area appeared to be a
predictor and possibly the cause of pancreatic cellular injury.43
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In cardiac surgery, hyperamylasemia was seen in 36% of patients with bypass
surgery, 59% of patients with valve replacement, and 69% undergoing both
procedures. Lipase was increased in 30% of the cardiac surgeries. It was found that
36% of the patients had an increase in s-amylase, which also correlated with the
severity of pleural effusion. This may have been due to the absorbance of s-amylase
from pleural fluid and/or from aspirated salivary secretions.44
In children with open heart surgery, it was found in a five year study that 54
patients had elevated amylase values or clinical pancreatitis following surgery. Of
these 33 had elevated amylase values only. The remaining exhibited pancreatitis along
with elevated amylase values. The etiology was proposed to be vascular in origin.45
(4) Renal insufficiency
Another cause of hyperamylasemia is abnormal renal function. In 1987,
Bardella reported that 33 out of 37 chronic renal failure patients had elevated amylase
levels, which correlated to the duration of the chronic renal failure. Pancreatic
amylase, however, was only slightly elevated in three of these patients. Blood urea
nitrogen (BUN) and serum creatinine showed no correlation to serum amylase.46
Values of amylase, along with lipase and trypsin, can become elevated when the
creatinine clearance is less than 50 mL/min.47 In chronic renal failure both the
amylase values and the Cm/Ccr are increased; however, the p-amylase to s-amylase
ratio is normal.48 These elevated amylase and lipase values have been reported in
chronic renal failure patients in the absence of clinical pancreatitis. However, amylase
values of greater than threefold in peritoneal fluid may be indicative of pancreatitis.49
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Interestingly, the total amylase was found to be significantly elevated in 34 end-stage
renal disease and was not reduced after hemodialysis. However, serum lipase, which
was likewise increased before dialysis, increased further after dialysis. The increase in
lipase correlated with the cumulative doses of heparin. P3 isoamylase was normal in
all patients.50
(5) Endoscopic retrograde cholangiopancretography
Endoscopic retrograde pancreatography (ERCP) is most helpful in determining
if blunt trauma injury to the pancreas has caused any ductal injury.51 However, this
procedure is not without its inherent problems. The first is that ERCP has been shown
to elevate all of the major pancreatic enzymes (serum amylase; lipase; trypsin;
elastase; serum alpha 1-antitrypsin and alpha 2-macroglobulin, two major pancreatic
protease inhibitors) in a study of 25 patients undergoing this procedure. The second is
that in three patients pancreatitis was induced by the ERCP.52 This ERCP induced
pancreatitis is not that uncommon. In another study the incidence was even higher. In
the follow up of 31 patients undergoing ERCP, 11 developed pancreatitis. The
incidence was the highest in which maneuvers, such as stent placement and balloon
dilation, were performed.53
(6) Eating disorders
In eating disorders, such as anorexia nervosa and bulimia, amylase levels as
high as 3000 U/L have been seen; however, p-amylase, lipase, and trypsinogen were
all normal.54 A study of 17 patients with eating disorders revealed that out of the six
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patients with hyperamylasemia, five had increased s-amylase while all had normal
lipase and p-amylase.55
(7) Macroamylasemia
The first reported case of hyperamylasemia due to the formation of an
amylase-globulin complex was by Wilding in 1964.56The term "macroamylase" was
first used by Berk in 1967 to describe persistently elevated serum amylase without
hyperamylasuria.56,57 Early sources indicated a preponderance of the s-amylase
coupled to the antibody;12however, more recent sources seem to indicate that the
amylase in macroamylase has an equal distribution of and p-amylase.58 The antibody
involved in macroamylase formation appears to be a monoclonal antibody.58 It has
been reported to be IgA, IgG or in some instances a polysaccharide(s) or
glycoprotein(s).59 The abnormally large complex, 150,000 to 2,000,000 Da,60 is
unable to be excreted in the urine even when there is no renal dysfunction. This
results in an elevated serum amylase levels.60,61 It is clinically important since it
appears to indicate a pancreatitis when there is none.
(8) Childhood etiologies
Etiologies of childhood pancreatitis are different than those of adults. Ziegler
stated that the most common causes of this disease in children were biliary tract
disease, trauma and congenital abnormalities, which frequently required surgery.
Biliary tract disease accounted for 33% of the pancreatitis cases, half of these were
related to a hematological disease, usually sickle cell. Of equal cause (33%) was
trauma with one third the result of child abuse. Other causes of childhood pancreatitis
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were: systemic disease, congenital abnormalities, and idiopathic.32 Other studies
showed similar etiologies to adults along with the category of drug induced
pancreatitis. However, there is disagreement as to the prevalence of various causes. In
Tagge’s study over an eleven year period involving 33 children, pancreatic causes
were diagnosed as: ductal abnormalities being the most common, with 12 cases;
trauma, 10; idiopathic, 4; gallstones, 3; drug induced, 3; and tumor, l. 35
A study of 61 children with acute pancreatitis showed that one third of the
cases were due to multisystem disease (Reye syndrome, sepsis, shock,
hemolytic-uremic syndrome, viral infections). Also as causes were blunt trauma,
structural defects, metabolic disease and drug toxicity, and idiopathic.33
A study over a 28 year period involving 48 children with pancreatitis showed
the following etiologies: 16 were idiopathic; 12 were drug induced, all of which were
the result of corticosteroid use; 9 were the result of blunt trauma; 7 had obstruction of
the pancreaticobiliary duct system; two were associated with sepsis; and two had
recurrent hereditary pancreatitis.34
(9) Other
Certain drugs are well known to elevate serum amylase levels. Morphine
raises amylase values up to three times normal because opiates constrict the sphincter
of Oddi, which causes back pressure into the pancreatic duct. Other drugs known to
cause an increase in amylase levels are choline, methacholine, chlorothiazide,
pancreozymin, and secretin.20
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Total body irradiation has resulted in increased serum amylase, most of which
was due to s-amylase, with only 27% due to p-amylase.24
Of a more unusual nature vitamin D intoxication has been validated as a cause
of recurrent pancreatitis. A patient was admitted four times with acute pancreatitis and
had serum calcium levels between 13.5 and 14.5 mg/dL. Questioning of the patient
revealed the intake of excessive quantities of vitamin D. When the vitamin D intake
ceased, the pancreatitis did not reoccur.62
There still remain some cases of hyperamylasemia that cannot be explained.
Warshaw investigated 117 patients whose amylase values remained elevated from
three to forty-eight weeks. Extensive investigation failed to show any reason for the
persistent elevation. Non pancreatic causes of their hyperamylasemia were attributed
to 79% of the cases as ascertained by polyacrylamide gel electrophoresis.
Macroamylasemia was the cause of 6%. Normal distribution of the isoenzymes were
found in 64% of the patients although they were high. Salivary amylase was elevated
in 9%63
b. Hypoamylasemia
Normal amylase values can occur even in patients with acute pancreatitis.
They can be related to 1) prevalence of alcoholic etiology, 2) a number of previous
alcoholic pancreatitis incidents, and/or 3) a duration of symptoms greater than two
days. Lipase values were elevated in 68% of this group. Acute pancreatitis in patients
with normal amylasemia is treated the same as those with an elevated amylase
levels.64 There has also been reported acute pancreatitis with low to normal amylase
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values when there is a pancreatic isoamylase deficiency. The acute pancreatitis was
confirmed surgically; however, the trypsin was elevated.65 Also low p-amylase values
have been reported in chronic exocrine pancreatic disease, such as chronic
pancreatitis, carcinoma of the pancreas, cystic fibrosis, and of rarer occurrence, a
congenital deficiency.66
4. Test for pancreatitis
a. Amylase
(1) Total
There are three main methods for determining amylase activity. First,
amyloclastic, in which the free substrate, usually starch, is measured. Second,
saccharogenic, in which the products (reducing sugars), are measured. Last
chromolytic, in which the substrate is composed of amylose or amylopectin
conjugated to a dye at C-2, and the resulting water soluble product (dye-glucoside) is
measured.12 Currently most commercially used tests for amylase employ the
measurement of the change in NADH absorbance at 280 nm or of the p-nitrophenol
released from a maltotetrose substrate. Other substrates that have been investigated
include: ethylidene-blocked 4-nitrophenyl-maltoheptaoside (EPS), where the
absorbance of 4-nitrophenol that is released is measured.67 Also, o-(4,6-oisopropylidene-a-D-glucopyranosyl)-( l-»4)-[o-a- D-glucopyranosyl-( l-*4])-5-o-a-Dglucopyranosyl-(l-*2)-a-D-fructofuranoside (IPG7F) has been used with the
subsequent determination of the oxidation rate of NADH.68 Likewise, 2-chloro-4nitrophenyl-a-maltotrioside can be used as a substrate, with the release and
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measurement of 2-chloro-4-nitrophenol.69These only determine total amylase, i.e.
they are nonspecific for p-amylase and often necessitate other tests to be performed
such as serum lipase.
Amylase has come under much scrutiny as to being the best indicator of
pancreatic disease. The usual indications for acute pancreatitis are abdominal pain and
a serum amylase levels three times the upper normal limit. Levels less than this value
are usually due to conditions other than acute pancreatitis.14 Lin suggested from his
studies that amylase values were diagnostic if the cutoff was three or four times the
upper limit, and at this level amylase determination was similar in sensitivity and
specificity to p-amylase and lipase determinations.70 Diagnostic accuracy of serum
amylase, p-amylase, lipase, trypsinogen and elastase-1 were: 96%, 96%, 93%, 91%,
and 84% respectively in 100 patients admitted as emergencies to the surgical
department and 27 proven acute pancreatitis patients in the study .7I Gwozdz likewise
found that on hospital admission all serum assays were equally sensitive; however, on
later tests, lipase, trypsinogen and elastase-1 were more sensitive than serum amylase.
The Cm/Ccr was found not to be differential.72
There appears to be a growing consensus that amylase values are not as
elevated in alcoholic causes as in other causes, particularly in biliary tract disease,
and that amylase values decrease more rapidly in time than some of the other serum
enzyme tests. The sensitivity of serum amylase, using greater than 1000 U/L, was
evaluated in 417 patients with acute pancreatitis; 62% were a result of gall stones,
25% from alcohol, 13% of unknown cause. On admission amylase was diagnostic,
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using greater than 1000 U/L, in identifying 96% of the mild cases and 87% of the
severe. At 48 hrs this was reduced to 33% and 48%, respectively.73 Hiatt found in his
study that hyperamylasemia due to biliary tract disease was higher, decreased more
rapidly and to a lower value than hyperamylasemia due to alcoholic pancreatitis.74 The
occurrence of normal amylase levels in acute pancreatitis can be related to 1)
prevalence of alcoholic etiology, 2) a number of previous alcoholic pancreatitis
incidents, and/or 3) a duration of symptoms greater than two days. Lipase values
were elevated in 68% of this group. Analysis of peritoneal fluid did not increase the
diagnostic sensitivity. However, bloody ascites and elevated amylase was helpful in
determining the presence of necrosis and hemorrhage.75
There does not appear to be a correlation between amylase levels and
pancreatic involvement as seen by computed tomography.26
(2) Isoenzymes
Pancreatic and salivary amylase can be separated by the removal of s-amylase
by a monoclonal antibody;76-77 wheat germ, which does not completely inhibit salivary
and does inhibit pancreatic to some extent;76 ion-exchange chromatography;78 or
electrophoresis.78 These methods are time consuming and lack either specificity or
quantification. However, the need to differentiate p-amylase from s-amylase remains,
and the presence of the P3 isoenzyme appears to be significant in the diagnosis of
acute pancreatitis.
Pancreatic amylase appears to be more sensitive than total amylase in the
diagnosis of acute pancreatitis, and P3 is even more specific for acute pancreatitis.
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Low p-amylase is significant in exocrine pancreatic insufficiency. Also, a reduced pamylase is suggestive of chronic pancreatitis.79 In pancreatic versus biliary disease, P3
was found to be the best determinate.80 Isoamylases measured by wheat inhibition and
cellulose acetate membrane electrophoresis revealed that increased p-amylase is
indicative of acute pancreatitis, and P3 isoamylase only occurs in acute pancreatitis.
Positive P3 by cellulose acetate electrophoresis has a positive efficiency of 93% and a
negative efficiency of 100%. Thus, the use of a P3 to exclude pancreatitis can
alleviate expensive radiological procedures.81 Isoelectric focusing also showed an
additional amylase fraction present in acute pancreatitis or pseudocysts similar to the
P3 fraction.10
P3 isoamylase has been evaluated in a group of 88 patients as an indicator of
complications of acute pancreatitis. It was found that 92% of the patients who had
complications (death, pseudocyst and recurrent pancreatitis) had an increase in P3
levels; whereas, in the group of patients who had acute pancreatitis who had no
complications at time of discharge only 7% had an increase in P3.82
During acute pancreatitis, it was found that the total and p-amylase levels were
appreciably higher than the upper levels of control. Also s-amylase was either very
low or not detected during the acute phase. During the recovery phase of the disease
the enzyme values tended to return to normal.83
Work has been done by several investigators on the inhibition of one of the
amylase isoenzymes by a monoclonal antibody to allow the determination of the other
isoenzyme. Steen developed an enzymatic colorimetric assay that utilizes two
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monoclonal antibodies that inhibit s-amylase. It was found that bilirubin did interfere
significantly with the assay.84 A monoclonal antibody coupled to plastic beads was
developed by Svens. It extracted p-amylase from the sample. The catalytic activity of
the s-amylase that was left was determined by its reaction with blocked p-nitrophenyl
maltoheptaoside as a substrate.85 Another test being investigated utilizing monoclonal
antibodies is based on the ability of two monoclonal antibodies to inhibit s-amylase
nearly completely; therefore allowing the measurement of p-amylase by its catalytic
action on the substrate, 4-nitrophenyl-alpha-D-maltoheptaoside.86 Another method
employed a monoclonal antibody against s-amylase that was coupled indirectly to
particles of polyvinylidene fluoride via a polyclonal goat anti-mouse immunoglobulin.
This was used to remove s-amylase, and the resultant p-amylase was determined.58
(3) Urinary
Urine amylase has come under scrutiny as to its value in the diagnosis of acute
pancreatitis. It has been suggested by some to be abandoned. In evaluating urine
levels [of amylase expressed as activity per volume (U/L) and activity per time
excreted (U/h) and of amylase/creatinine clearance ratio] and serum levels (of
amylase, elastase, lipase, and trypsinogen) at admission and repeatedly during
hospitalization, individual serum assays have the highest sensitivity and specificity.87
b. Other tests
(1) Lipase
The diagnosis of acute pancreatitis is most typically based on the clinical
picture and elevated serum amylase. Total amylase determination has the advantage of
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availability, technically simple, and at 24 hours of onset of pain as sensitive as lipase,
pancreatic isoamylase, immunoreactive trypsin or elastase. However, after 24 hours it
becomes one of the least sensitive. Lipase has the advantage of being more specific
and almost as sensitive as amylase.88 Of interest the pancreas has four and a half
times more lipase than amylase.15 The other tests (pancreatic isoamylase,
immunoreactive trypsin and elastase) are not readily available to most hospital
laboratories. These tests are best used in cases of difficult diagnosis. Other diagnostic
procedures, such as ultrasonography, which aids in determining the extent of
involvement of the biliary tract in the pancreatitis; and computed tomography
(CECT), which is used in evaluating the extent of pancreatic necrosis, are helpful in
determining the course of treatment.88 Early operation is suggested in severe acute
pancreatitis.75
In hyperamylasemic patients with the possibility of acute pancreatitis, serum
lipase levels remain higher longer than either the pancreatic or total amylase. On
hospital admission of acute pancreatitis patients, there is a poor correlation between
lipase and serum amylase. Apple found that the efficiency of p-amylase, lipase, and
total serum amylase was 94.1%, 76.5%. and 64.7%, respectively.15 Of p-amylase,
lipase, total serum amylase, urine amylase, and serum amylase, Parodi reported that
the best indicators for acute pancreatitis were p-amylase and lipase, with 96% and
95% accuracy.89 Pancreatic lipase appears to have the same temporal sequence as P3;
however, at present, lipase is more convenient (more available and shorter turn
around time).90
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The lipase levels are greater in alcoholic pancreatitis as compared to gall
stone pancreatitis; whereas, in gallstone pancreatitis the amylase levels tend to be
higher.91 It was found that the lipase values of proven pancreatitis ranged from 1011
to 25,706 U/L; whereas, in a group of 202 asymptomatic alcoholics the range was
from 34 to 600 U/L.92 The ratio of lipase to amylase expressed in multiples of the
upper normal limit of both indicated that a ratio of 2 or greater was indicative of
alcoholic pancreatitis, and less than 2 implied a nonalcoholic etiology.91 Gumaste
concluded that lipase was a better determinant for diagnosing acute alcoholic
pancreatitis than amylase.92
There have been reported some negative aspects of lipase testing. Tereault
reported some surprising results of lipase values with the Ektachem 700 analyzer.
Amylase has been reported to be more sensitive; while lipase has been reported to be
more specific for pancreatitis. Out of 493 patients who had both tests ordered, it was
found that 103 had values greater than the upper reference limit. Within this group
lipase had 100% sensitivity and 84% specificity; while amylase had 72% sensitivity
and 88% specificity.93 In rare cases, elevated serum lipase levels have been reportedly
due to macrolipasemia.94
(2)

Pancreatic phospholipase A2

Pancreatic phospholipase A2 (PLA2) has been evaluated as an indicator of acute
pancreatitis since it is released from injured pancreatic acinar cells.95 PLA2 was
increased in 60% of the chronic pancreatitis patients, 67% of pancreatic cancer
patients, and 27% of non-pancreatic disease patients (most often in renal failure
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patients).96 However, although present in acute pancreatitis, the pancreas is not the
only source of PLA2.95 PLA2 levels showed no correlation with lipase or amylase but
was related to the prognosis of acute pancreatitis. Elevated values have been seen with
necrotizing pancreatitis and septicemia. Normal phospholipase A2 values were seen in
uncomplicated acute pancreatitis.97
(3) Immunoreactive trypsin
Trypsin-a 1-proteinase inhibitor (alpha 1PI) complexes and trypsinogen
comprise immunoreactive trypsin.98 Immunoreactive trypsin (IRT) was shown to
minimally correlate with serum amylase in patients with acute pancreatitis; however,
in patients who had persistent IRT with amylase values that had returned to normal,
there were pancreatic complications, pseudocyst, and hemorrhagic pancreatitis. IRT
may be useful as a prognostic tool.99 Lankisch summarized that the patient’s recovery
pattern was best reflected by total amylase and p-amylase levels, and that trypsin in
cases of delayed diagnosis was a good indicator.100 However, trypsin-a 1PI complexes
can be elevated in conditions other than acute pancreatitis.98
(4) Acute phase proteins
Certain acute phase proteins tests revealed that a-1-antitrypsin was the most
sensitive index to diagnose chronic pancreatic disease, and C-reactive protein (CRP)
reflected the stage of the disease best. These were independent of each other.
However, all of the acute phase proteins (C-reactive protein, ceruloplasmin and alpha1-antitrypsin) were all influenced by liver damage.101 Out of CT, CRP, PLA2, and
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amylase; CT and CRP were determined to be the best indicators of the prognosis of
acute pancreatitis.102
(5) Miscellaneous
Other diagnostic enzymes currently being investigated for their use in the
diagnosis of pancreatitis are carboxylic ester hydrolase and elastase 1. Carboxylic
ester hydrolase can be present in acute pancreatitis without an elevated amylase.103 It
was also found that carboxylic ester hydrolase remained elevated in necrotizing
pancreatitis for 10 days but decreased in acute interstitial pancreatitis. Amylase values
in acute interstitial pancreatitis were higher than in those of necrotizing pancreatitis.104
Serum elastase 1 sensitivity was superior to lipase, p-amylase and immunoreactive
trypsin when the cutoff was two times the upper limit; however, its specificity was
less than lipase or p-amylase. In cases of renal insufficiency, it correlated with
amylase and p-amylase.105 Serum elastase is reported to be increased to a greater
extent than serum amylase in acute pancreatitis, and it remained elevated longer than
amylase.106,107 Serum elastase-1, amylase, lipase, and trypsin-like immunoreactivity
were all elevated at 24 hours in acute pancreatitis patients. However at 10 days only
serum elastase-1 and trypsin remained elevated in 90% of the acute pancreatitis
patients.108 Ventrucci found amylase, pancreatic isoamylase, lipase, trypsinogen, and
elastase 1 were all elevated on the first day of clinical symptoms. The greatest
increase was seen in p-amylase; the lowest with elastase 1. With time, all serum
enzyme levels decreased in a similar fashion except for the elastase 1, which
remained elevated in all patients longer than the rest.109
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Serum enzyme values (amylase, pancreatic isoamylase, lipase, trypsinogen,
and elastase 1) vary greatly in chronic pancreatitis patients during remission, and the
majority of assays are normal (60%). In 67% of chronic pancreatitis elastase was
within normal range.106 Likewise in pancreatic cancer highly variable enzyme levels
are seen. Elastase 1 was the most frequently elevated enzyme (35%) in both groups.110
Gullo had previously found similar findings in chronic pancreatitis and carcinoma of
the pancreas.107
The most common symptom in acute pancreatitis is severe abdominal pain. In
evaluating the severity of and determining the etiology, ultrasonography and computed
tomography are useful and aid in deciding the treatment. ERCP is the most sensitive
for diagnosing biliary lithiasis. Pancreatic necrosis has also been detected by Creactive protein, PMN-elastase, and trypsinogen activation peptides.111
c. Developmental tests
(1) Radioimmunoassays
Some of the first uses of monoclonal antibodies in diagnostic testing utilized
radioactive isotopes. These methods were specific and sensitive; however, they have
lost their importance in the clinical laboratory due to the storage and waste
management of the radioactive materials. The structural differences between samylase and p-amylase are small but significant enough that they should enable a
monoclonal antibody to be produced to each.112 A method by Fujita employing a
monoclonal antibody to p-amylase has been developed utilizing a radioimmunoassay
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which shows negligible cross-reactivity to s-amylase. His test detects levels as low as
7 mg/L.113
(2) Enzyme immunoassays
The problem of waste management and storage of radioactive isotopes has led
the way for the development of a second generation of diagnostic tests that employ
monoclonal antibodies. A variety of tests that employ monoclonal antibodies are now
under investigation. Panozzo expressed apprehension in the use of a monoclonal
antibody for diagnosing chronic pancreatic disease. He stated that the monoclonal
under his investigation had limitations in its specificity although it was sensitive to
pancreatic inflammation.114
These tests belong to the group commonly called enzyme immunoassay (EIA).
There are two main types of EIA: homogeneous, also called enzyme multiplied
immunoassay technique (EMIT), and heterogeneous, also called enzyme linked
immunosorbent assay (ELISA). In the EMIT, the antibody is added to the patient
sample. The enzyme labeled antigen is then added. The sample competes with an
enzyme labeled antigen for the antibody. If the antibody combines with the enzyme
labeled antigen, the enzyme reaction is inhibited by the antibody either physically or
by changing the conformation of the enzyme; thus the more antigen in the sample, the
more enzyme labeled antigen that can react, which results in an increase in
absorbance. The resultant color is directly proportional to the amount of antigen in the
sample. Since there is no phase separation, the assays can be automated and quickly
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performed. There is the disadvantage of interference from other constituents in the
sample since there is no phase separation. This method is diagramed in Figure 1.
The ELISA requires phase separation of the antigen-antibody complex and the
unbound constituents. There are two types of ELISA: the competitive, in which the
resultant color is inversely related to the amount of antigen in the sample, and non
competitive, also called the sandwich assay, in which the resultant color is directly
proportional to the amount of antigen in the sample. In the competitive assay the
antibody is coated on the microwell. The sample with the antigen and an enzymeconjugated antigen are added. The competition of the two antigens results in the
amount of enzyme that is bound being inversely proportional to the amount of the
antigen in the sample. The excess constituents are washed off, a substrate is added,
and the resultant product is determined by a colored assay. This method is shown in
Figure 2.
In the sandwich assay, there are two binding sites to the antigen. Again the
well can be coated first with an antibody. The sample with the antigen is added, the
unbound constituents washed off, and an enzyme-conjugated antibody (a second
antibody) that is specific for a different epitope of the antigen is added. The excess is
washed off, and again the substrate is added that results in a colored product being
formed. The resultant color is directly proportional to the amount of the antigen
present. Figure 3 demonstrates this reaction.
A number of researchers have produced pairs of monoclonal antibodies for
either p-amylase or s-amylase. Diamandis determined p-amylase levels by the use of
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Figure 1
Principle of the homogeneous enzyme immunoassay
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Figure 2
Principle of the competitive heterogeneous enzyme immunoassay
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Figure 3
Principle of the sandwich heterogeneous enzyme immunoassay
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two monoclonal antibodies. One was immobilized to a microtiter well; the other was
biotintylated. By the addition of streptavidin which was labeled with an europium
chelator, the resulting fluorescence was measured, and the immunocomplex
quantitated. The antibodies used showed low cross reactivity with s-amylase.115
Fujisawa also has reported success in using two monoclonal antibodies specific for pamylase. This work also showed little cross reactivity to s-amylase.116Another
enzyme immunoassay that employed two monoclonal antibodies for detecting pamylase, the latter being conjugated with peroxidase, was investigated by Fujisawa.116
Rosenblum has produced two monoclonal antibodies that bind p-amylase and do not
block the active site of the enzyme. Good correlation with isoamylase determination
by electrophoresis was obtained.117
A test strip that is composed of monoclonal antibodies to s-amylase has been
produced by Lorentz. It has been demonstrated to be useful in cases of slightly
elevated amylase levels.118
B. Objectives
The purpose of this research was to develop a solid phase enzyme
immunoassay for determining p-amylase and s-amylase. This method involves the
immobilization of cycloheptaamylose to the microwell. Subsequently, the pamylase and s-amylase in the sample bind to the inhibitor. The respective levels of
p-amylase and s-amylase are determined by the reaction of the specific monoclonal
antibody against p-amylase or s-amylase. The prevalence of p-amylase and s-
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amylase in hyperamylasemic patients were determined. The order of development
and specific objectives were as follows:
1.

Isolation and purification of p-amylase and s-amylase.

2.

Production of monoclonal antibodies against the purified p-amylase and
s-amylase by hybridoma technique.

3.

Purification and characterization of the monoclonal antibodies.

4.

Employment of the purified monoclonal antibodies for development of a

solid phase enzyme immunoassay (EIA) for serum amylase.
5.

Characterization of the developed solid phase EIA method and comparison
with electrophoresis for determination of p-amylase and s-amylase in
hyperamylasemic patients.
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Chapter I I
EXPERIMENTAL
A. MATERIALS:
A ll chemicals were Reagent Grade unless otherwise stated.
AAPER Alcohol and Chemical Co.: ethanol (USP)
Aldrich: 1,4 butanedioldiglycidyl ether
Allied Chemical: dibasic sodium phosphate
American Type Culture Collection: NS1 (non-secreting mouse myeloma)
cells
Becton Dickson: 1 cc and 3 cc syringes; 30 G, 25 G, 22 G, 18 G
Corning: 24 microwell plate
Dynatech Laboratories, Inc.: Immulon 1 Removawell strips
E.M . Science: ethyl ether anhydrous, sulfuric acid
Ethicon: ethicon silk 4.0
Falcon: 25 cm2 50 mL culture flask, 10 x 35 mm tissue culture dish;
15 mL sterile centrifuge tube
Fisher: sodium meta periodate, sodium acetate, sodium hydroxide,
dextrose, citric acid monohydrate, glycerin, boric acid
Gelman Instrument Company: Cellulose electrophoresis strips
(Super Seprapore)

31
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Gibco: Iscove’s medium (IMDM), Fetal bovine serum (FBS);
penicillin/streptomycin (lOOx); Hybridoma-Serum Free Media
JRH Biosciences: HAT selective supplement (lOOx)
J. T. Baker Chem Co.: Iodine, sodium borohydride, cyclohexane
Jackson Laboratories: BALB/CByJ mice
Kai: Miltex Stainless steel sterile surgical blade
M allinckrodt: sodium chloride, methanol, ammonium chloride
M illipore: 0.22 nm filter unit with filling bell
Monoject, Division of Sherwood Medical: heparinized capillary tubes
Nunclon: 96 microwell plate
Oxford Labware: critoseal
Pharmacia Diagnostics: Phadebas Amylase test tablet
Sigma: salivary a amylase, sodium phosphate (monobasic anhydrous),
Trizma Base (Tris [hydroxymethyljaminomethane),
cycloheptaamylose (CHA, (3 cyclodextrin), Sepharose 6B,
phenylmethylsulfonyl fluoride, j8 glycerophosphate, amylose,
3,3’ ,5,5’-tetramethylbenzidine (TMB); Goat anti-Mouse IgG (whole
molecule) Peroxidase Conjugate; Polyethylene glycol
(PEG);lipopolysaccharide (LPS); sodium bicarbonate; Ovalbumin
(OVA); polyoxyethylene-sorbitan monolaurate (Tween 20); HT
media supplement:hypoxanthine 5 x 10'3 M thymidine 8 x 10"4 M,
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50 X (HT); RPMI 1640 medium, with L-glutamine, without sodium
bicarbonate;sodium azide, horse serum albumin, Protein A on
Sepharose 4B fast flow, N-hydroxysuccinimide (NHS),
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),
urea-hydrogen peroxide, barbital buffer, Sigma ImmunoType Mouse
Monoclonal Antibody Isotyping Kit
Spectrum Medical Industries, Inc.: Spectra/Por dialyzing tubing 23 mm x
100 ft, m.w. cut off 6,000-8,000; and 10 mm x 50 ft, m.w. cut off
12,000-14,000
Voluntary Hospitals o f America Supply Company: VHA Level I and
VHA Level D (normal and abnormal human serum controls)
B. EQUIPMENT
Amicon Filtration System, model 12 and 52 with a YM10 filter
Beckman Appraise Densitometer
Beckman Microzone Cell Model R-101 Electrophoresis chamber
Beckman Model CDS-200 Computing Densitometer Scanner
Beckman Model TJ-6 centrifuge
Beckman sample applicator for cellulose acetate electrophoresis
Bio-Tek Instruments Model 207 Microplate reader
ISCO Model UA-5 Absorbance/Fluorescence Monitor
Nicolet 5PC FT-IR Spectrometer
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Rotomix Type 48200 by Thermolyne Sybron
Warring Commercial Blender
C. Methods
1. Preparation of antigens
a. Pancreatic amylase
(1)

Extraction

The visible fat was trimmed from a normal human pancreas obtained from
autopsy; the pancreas was then weighed. A buffer (containing 320 mg
phenylmethylsulfonyl fluoride, 50 mM of /3-glycerophosphate, and 150 mM of
NaCl, pH 7.0) was added to the pancreas in a volume of 5:1 was placed in a
Warring blender with the pancreas. The pancreas was homogenized with the buffer
for 60 s. The resulting mixture was centrifuged at 4°C for 30 min at 5000 g. The
fat rose to the top while the other debris remained at the bottom. The liquid
portion was poured through four layers of gauze to retain the fatty material.
(2)

Purification
(a)

Production of cycloheptaamylose Sepha

A sufficient quantity of Sepharose 6B was washed and dried on a course
glass filter funnel with water to yield 20 grams. Twenty mL of 0.6 M NaOH
containing 2 mg/mL sodium borohydride was added, followed by the addition of
20 mL of 1,4-butanediol diglycidyl ether. The mixture was divided evenly between
two 50 mL plastic centrifuge tubes. These were mixed on a platform rocker for 8
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h at 25°C. The mixture was poured onto a course glass filter funnel and washed
with 4 L of deionized H20 119. A schematic of the reaction is shown in Figure 4.
Twenty grams of the freshly prepared epoxy-activated Sepharose 6B that
had been dried on a glass filter funnel was combined with 1500 mg of
cycloheptaamylose and 60 mL of 0.1 M NaOH in two 250 mL Erlenmeyer flasks.
The flasks were put on a shaker in a 45 °C water bath for 19.5 hr. After
incubation, the coupled Sepharose was washed for 30 min with approximately 4 L
of deionized water on a glass filter funnel with slight aspiration. It was then
washed with dextrose (25 mg/mL, approximately 500 mL) for 30 min with no
aspiration. It was washed again with approximately 4 L of deionized water for 30
min with aspiration. It was finally washed with 4 L of 50 mM sodium acetate
buffer pH 4.8 for 2 hr with no aspiration.120121 The final reaction is shown in
Figure 5.
(b) Affinity chromatography
Equal portions (70 mL of each) of the above liquid portion (p-amylase
homogenate) were mixed with a 50% solution of CHA-Sepharose in equilibration
buffer (50 mM sodium phosphate and 50 mM of NaCl, pH 6.9) for 10 min in a 20
x 5 cm column. The column was then connected to a ISCO Model UA-5
Absorbance/ Fluorescence Monitor with the wavelength set at 280 nm. A sample
of the eluent was tested to determine if any amylase was still present. One hundred
/xL of the sample were added to 100 /xL of working substrate solution and
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Figure 4
Activation of Sepharose with 1,4-butanediol diglycidyl ether
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Figure 5
Reaction of coupling CHA to sepharose

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

37

<
I

O

+
O

+

<

I
01
0
.c
4>4

0

0)
-C
•4 -1

a)

-g
'o
>.
03
TJ
2
13
0

C

to

■M

_Q
i

>
■g
'o
>
g)
13
o
0

c
0
3

-*—*

XI

■

LU

CO

0

cc

<
1

■

LU
C/3

O

<
CL
LU
CO

cr

<

<

CL

LU
CO

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

38

incubated at 37 °C for 20 min. Then 850 /xL of working iodine solution were
added. Negative results for amylase appeared blue purple in color; whereas,
positives appeared brown to dark yellow. The eluent was saved if it tested positive
for amylase, and the extraction was repeated with reequilibrated CHA-Sepharose
till no amylase was left in the eluent. The CHA-Sepharose-amylase was washed
with the equilibration buffer till the base-line was stable. The amylase was eluted
with 8.0 g/L of CHA in equilibration buffer. The eluent was monitored at 280 nm,
and the eluent corresponding to the recorder peak was collected. The gel was
reequilibrated by removing it from the column, placing it in a glass filter funnel,
then washing it with the equilibration buffer (approx 100 mL). Next, it was
washed with 1 N NaCl (approx 75 mL). Finally, it was washed and re-equilibrated
with equilibration buffer (approximately 150 mL). The p-amylase was dialyzed in
6 L 10 mM PBS, pH 7.4, overnight with 2 changes of buffer to remove the CHA.
A ll of the eluents were concentrated with an Amicon Ultrafiltration System, model
12 and 52 equipped with a YM10 filter. The concentrated p-amylase was stored in
1 mL aliquots at -80°C m.
b.

Salivary amylase

The s-amylase was purchased from Sigma. The solid (19 mg, 2500 units,
1450 units/mg protein) contained 1.724 mg protein and was reconstituted with 10
mL of 1 mM CaCl2. The amylase was dialyzed with 6 L of 10 mM PBS, pH 7.4,
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to remove the (NH4)2S04 in which it was stored. The buffer was changed 2 times
every 8 hours. The s-amylase was frozen in 1 mL aliquots at -80°C.
2.

Production of antibodies
a.

Im m unization of mice

A 5 week old BALB/CByJ male mouse was anesthetized by an
intraperitoneal injection of pentobarbital (40-70 mg/Kg body weight). The animal
was placed on its right side, and the area exposed on the left side of the abdomen
was washed with 70% ethanol. A 0.5-1.0 cm incision was made aseptically into
the left abdomen below the rib with small sterile scissors, exposing the spleen but
not cutting through the peritoneum. Into the spleen, 100 nL of the p-amylase,
which was diluted with 10 mM PBS, pH 7.4, to a concentration of 400 /xg/mL (40
fig) were injected with a 1 mL syringe, 1/2 in 30 G needle. Using ethicon silk 4.0,
two stitches were made aseptically to close the skin. The first booster of 20 fiL of
p-amylase, which was diluted with 10 mM PBS, pH 7.4, to a concentration of 2
mg/mL (40 fig) was given 11 days after initial injection using a 30 G needle via
the tail vein. A second booster was given 13 days after the initial injection in the
same manner as the first booster. The procedure was repeated with another mouse
using s-amylase as the antigen.
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b.

Titer determinations
(1)

Antigen well preparation

The Immulon 1 microtiter wells were coated with 200 L of p-amylase at a
concentration of 1 jttg/mL, in a coating solution. After an incubation of a minimum
of five hours (or overnight), the wells were washed 7 times with 10 mM PBS, pH
7.4, with 0.1 % Tween followed by 7 times with deionized water. The wells were
air-dried for approximately 10 min. Blocking of non specific binding was
performed with a 0.3 % OVA in coating solution, 200 piL/well. After incubation
for 2 hours, the wells were again washed 7 times with 10 mM PBS, pH 7.4, with
0.1 % Tween, followed by 7 times with deionized water and air dried for
approximately 10 min. The procedure was repeated using s-amylase as the antigen
with another set of wells.
(2)

Titer assay

A serum titer assay was performed to determine if sufficient antibodies
were produced from the immunizations by the following procedure. A small
incision was made in the tail of the mouse with a sterile stainless steel surgical
blade, and a heparinized capillary tube was used to collect blood. The tube was
filled approximately 2/3, then the end of the tube was sealed with critoseal and
centrifuged at 1000 g for 10 min. Five /xL of plasma was removed and serially
diluted with 10 mM PBS, pH 7.4. Dilutions were 1:200; 1:400; 1:800; 1:1600;
1:3200; 1:6400; 1:12800; 1: 25600; 1:51200; 1:102400; and 1:204800. To the
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antigen-coated wells, 200 /xL of each dilution were added and incubated at room
temperature for at least 2 hours. Again they were washed 7 times with 10 mM
PBS, pH 7.4, with 0.1 % Tween, followed by 7 times with deionized water and air
dried for approximately 10 min. Goat-anti-mouse IgG-HRPO, 200 ptL/well, were
added at a concentration of 5 /xL diluted to 25 mL (1:5000) with 10 mM PBS, pH
7.4. The wells were incubated at room temperature for 1 hr. The wells were
washed 7 times with 10 mM PBS, pH 7.4, with 0.1 % Tween, followed by 7 times
with deionized water and air dried for approximately 10 min. To the wells, 100
nL of buffered peroxide solution were added followed by 100 /xL 3, 3’ , 5, 5’tetramethylbenzidine (TMB) solution. The wells were mixed on a rotator till a blue
color appeared. The reaction was stopped with 50 /xL of 2 N H2S04. The wells
were then read on a microplate reader at 450 nm, and the titer determined.
I f the titer was not at least a hundredfold increase from the base line, the
mouse was boosted in a similar manner every 2-3 weeks. A significant titer was
expected to be at least a hundredfold difference of undiluted serum. If the titer was
significant, the animal was sacrificed 1-3 days after the final boost. The spleen
cells were harvested for cell fusion.
The same procedure was used utilizing s-amylase as the antigen in a second
5 week old BALB/CByJ male mouse.123
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c. Cell fusions
A ll dissection tools were sterilized in a hot oven (100°C) overnight. The
day of the fusion, 70% ethanol was added to the dissection tray prior to use. The
following were put in a 37°C water bath: MC-IMDM (25 mL), Serum Free
Medium (40 mL), FBS (10 mL), LPS solution (0.2 mL of 4 mg LPS/mL of
IMDM), HAT (50 X) (2.0 mL). A 50% warm PEG solution was prepared by
autoclaving 1 g PEG for 15 min at 15 psi, then adding 1 mL RPMI 1640 when the
PEG was warm.
NS-1 cells were grown in complete medium in a 37 °C incubator with 100%
humidity and 5 % C02 in 50 mL Falcon tissue culture flask to yield 2 x 107 - 5 x
107 NS-1 cells (1/2 to 1/5 the number of spleen cells for fusion). On the day of
fusion they were transferred to a 15 mL sterile centrifuge tube and centrifuged at
100 xg at room temperature for 5 min, and the supernatant was aspirated. They
were resuspended in 5 mL Serum Free Media.
The mouse was boosted 1-3 days prior to fusion day. (If mouse was 8
weeks or less of age, the thymus was saved for thymocyte harvesting.) The mouse
was sacrificed by cervical dislocation, and the abdomen was soaked with 70%
ethanol. The spleen was carefully removed, using sterile technique. The spleen
was placed in a 10 x 35 mm culture dish containing Serum Free Media and rinsed.
It was transferred to another dish and rinsed again. The tissue was gently tom
apart with forceps, minced with scissors, then mixed with the use of a 1-mL
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plastic syringe. The spleen cell suspension was transferred through a sterile wire
sieve, rubbing the tissue against the sieve, into a sterile 15 mL sterile centrifuge
tube. A sample was taken and counted to determine the number of spleen cells.
For fusion 1.0 x 10 8 spleen cells were needed. The suspension was centrifuged at
100 xg for 5 min at room temperature, and the supemate was removed by suction.
To dissolve the erythrocytes that were present, 5 mL 0.85% NH4C1 solution were
added to tube and allowed to stand at room temperature for 5 min. The solution
was centrifuged as before, and the supernatant aspirated. The pellet was
resuspended in 5 mL Serum Free Media.
Thymocytes were obtained from a BALB/CByJ 5 weeks old mouse.
(Thymocytes from the boosted mouse were used if under 8 weeks of age.) The
mouse was sacrificed by cervical dislocation. The chest and throat area were
sterilized by washing with 70% ethanol. The chest cavity was opened by standard
procedure, and the thymus removed. It was rinsed with 3 mL Serum Free Media
in a 10 x 35 mm tissue culture dish to remove as much blood as possible. It was
transferred to a second dish and rinsed again. In a third culture dish, the gland was
carefully tom with forceps to free the thymocytes into the 3 mL of the media. The
tissue-cell mixture was further mixed with a 1 mL plastic syringe. The cell
suspension was transferred through a sterile wire sieve, rubbing the thymus tissue
against the sieve, into a sterile 15 mL tube, and a sample of the cell suspension
was counted. Sufficient quantity was transferred to a 15 mL sterile tube to yield
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2 X 108 thymocytes. The cell suspension was centrifuged at 100 xg for 5 min at
room temperature. The supernatant was removed by suction. The cell pellet was
resuspended in 1.4 mL 2X IMDM. The suspension was combined with 10 mL of
FBS, 1 mL HAT (100X), and 0.2 mL of LPS solution (4 mg LPS/mL IMDM),
plus 2.4 mL D.W. [Final volume 15 mL, Solution T]
Cell fusion was accomplished by the following schematic in Figure 6.
d.

Hybridoma clone selection

A 96 well plate was prepared by adding 250 /xL of complete medium that
contained 1 x 104 to 105 thymocytes in each well. After approximately 10 days
incubation after cell fusion, clones were selected that were smooth and
homogeneous, had one center with well defined edges, and were not closer than
1.5 mm. The size of clone was between 0.5 mm and 1 mm. Using a dissecting
scope in a closed plastic hood, each clone was siphoned with 50 /xL pipette and
dispersed one clone per well into the aforementioned 96 well plate. The clones
were fed 1 drop (25 jtxL) of 1 x 104 to 105 thymocytes per well once a week, two
times.124
e.

Hybridoma clone propagation

When the media turned yellow, indicating good cell growth, the well was
mixed and 150 /jlL were transferred into one well of a 24 well plate containing 1
mL of complete medium with 1 x 104 thymocytes. The 150 /xL were replaced with

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

Figure 6
Cell fusion schematic
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Ratio
1:5

.0 .9

Spleen Cells
(total 108)
in 5 mL Seram Free Media

NS-1 Cells
(total 2 x 107)
5 mL Serum Free Media
50 mL sterile Tube

1 Add spleen cells to NS1 in 50 mL tube
I

Centrifuge 500 rpm, 5 min;
Remove supemate by suction

1 Take up 1 mL 50% PEG & add over
1 1 min
1 -* 0.1 mL added each 6 sec
I Add 2 mL Serum Free Media over
i 2 min, stirring slowly
1 -* 0.1 mL added each 6 sec
1 Slowly add 7 mL more Serum Free
I Media the next 2-3 min
1 Centrifuge @ 1000 rpm, RT, 5 min

1 Remove the supemate by suction
1 Add 15 mL of Solution T to resuspend
1 the pellet
* Add to 25 mL 37°C MC-IMDM in a 50
I mL tube; Mix for 3-4 min by slowly
1 inverting
Dispense the 40 mL into culture dishes (1.5 mL per dish).
Incubate in 37°C incubator with 100% humidity and 5% C02.
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new complete medium with thymocytes. When a well turned yellow the second
time, a back up was made in another 96 well plate.
f.

Hybridoma clone screening

Wells coated as previously described with either s-amylase or p-amylase
were used to screen antibody production by the clones. After 10-14 days of
growth, 100 /xL of coating solution were pipetted into each well. Then 100 /xL of
supernatant of each clone well that had a yellow supernatant were added into each
test well and incubated at room temperature for 2 hours. The wells were washed 7
times with 10 mM PBS, pH 7.4, with 0.1 % Tween, followed by 7 times with
deionized water, and dried for 10 min. Goat-anti-mouse IgG-HRPO, 200 /xL/well,
were added at a concentration of 5 /xL diluted to 25 mL (1:5000) with 10 mM
PBS, pH 7.4. The reaction was incubated at room temperature for 1 hr, then
washed 7 times with 10 mM PBS, pH 7.4, with 0.1 % Tween, followed by 7 times
with deionized water, and finally air-dried for 10 min. To the wells, 100 /xL of a
buffered peroxide solution and 100 /xL 3, 3’ , 5, 5’-tetramethylbenzidine (TMB)
solution were added. The plate was mixed on rotator till a blue color appeared.
The reaction was stopped with the addition of 50 /xL of 2 N H2S04. The
absorbance was read at 450 nm in a microplate reader; zero was set with a goatanti-mouse IgG-HRPO blank.
Clones were selected that had good growth, were highly reactive with their
respective antigen, and were negative for the opposite antigen. Also, a third group
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was selected that showed good cross reactivity to both antigens. These were
transferred to 24 well plates, which contained 2 mL/well of complete medium and
incubated at 37°C in 100% humidity and 5% C02. From each of the above clones,
hybridoma cells were frozen for back up.
g. Cultivation of antibodies
(1)

Production of antibodies in vitro

As the hybridoma cells continued to grow, the supernatant o f the culture
medium turned acidic (yellow in color). At this time 1 mL of the supernatant was
transferred aseptically to a 50 mL centrifiige tube and stored at -20 °C till sufficient
volume of supernatant was collected. One mL of complete medium was added to
replace the supernatant that was removed. Two cell lines, 2PE10 and 2PC2, were
also grown in Serum Free Hybridoma Media utilizing the same methodology.
(2)

Production of antibodies in ascites fluid

An 8 week old BALB/CByJ male mouse was primed with 0.5 mL pristane
intraperitoneal 3-4 days prior to hybridoma injection. Incomplete Freund’s
Adjuvant was also injected intraperitoneal as a primer in some of the mice (0.25
mL, 7-10 days prior to hybridoma injection). The hybridoma cells that were grown
in complete medium were counted and sufficient quantity was transferred to a
centrifuge tube to yield 2 mL of 1 - 2 x 107 cells/mL needed for injection. After
centrifuging, the resultant supernatant was aspirated. Two mL of serum free
medium was added to the pellet, and the cells were resuspended. The cells were
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drawn into a 3 cc syringe with no needle attached. After the cells were in the
syringe, a 25 G needle was attached, and the air was removed from the syringe
and needle bringing the volume to 2 mL. The mouse’s abdomen was washed with
70% alcohol, and 2.0 mL of 1 - 2 x 107 cells/mL were injected in intraperitoneal.
The mouse was checked for the production of ascites fluid. Beginning at
one week and as late as three weeks depending on the growth rate of the cell line,
the mouse would exhibit an extended abdomen. When the abdomen became
distended, it was washed with 70% ethanol. The peritoneum was punctured with
an 18 G needle on a 3 cc syringe, and the ascites fluid was collected drop-wise
into a sterile test tube while applying gentle pressure to the sides o f the abdomen
of the mouse. The aspirate was frozen, and each succeeding tap of ascites fluid
was frozen till the mouse expired. The procedure was repeated with each
hybridoma cell line used.125
h.

Purification of antibodies

The cell culture supernatant or ascites fluid was centrifuged for 5-10 min at
approximately 100 xg, and the supernatant measured. A Protein A-Sepharose
column was washed with 10 mM PBS, pH 7.4, with the monitor set at 280 nm
until the baseline was stabilized. The supernatant of the cell culture or ascites fluid
was applied to the Protein A-Sepharose column. The first peak (1st fraction)
containing the unwanted protein was discarded. The column was washed with 10
mM PBS, pH 7.4, until the baseline was again reached and stable. The column
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was then washed with the elution buffer, and the effluent (2nd fraction) was
collected into a flask. The elution was continued until the base line was again
reached and was stable. The effluent in the flask was adjusted to pH 7.0 with 1.0
N NaOH. The effluent, which contained the IgG fraction, was transferred to
dialyzing tubing then dialyzed twice in 6 L of 10 mM PBS, pH 7.4, for 8 hrs
each. The dialysate was concentrated with an Amicon ultrafiltration system using a
YM-10 filter, and the concentrate was stored in 1 mL aliquots at -20°C. The
Protein-A Sepharose column was washed and stored in 0.02% sodium azide in 10
mM PBS, pH 7.4, at 4°C.126
i.

Conjugation of antibody with horseradish peroxidase (HRPO)

Sufficient HRPO was dissolved into 0.1 M sodium acetate buffer, pH 4.5,
to give a final concentration of 10 mg/mL. Equal volumes of the HRPO solution
and 0.1 M NaI04 were mixed and allowed to react at room temperature for 5
minutes. The mixture was then dialyzed in 6 L of 10 mM sodium acetate buffer,
pH 4.0, overnight at 4°C with two changes of the solution. The antibody to be
labeled with HRPO was put in a 0.1 M carbonate buffer, pH 8.3, to a final a
concentration of 2 mg/mL. Equal volume of periodate oxidized HRPO and the
antibody solution were mixed and allowed to stand at room temperature for 4
hours. The reaction was stopped with a NaBH4 solution (1 mg/mL) in a volume
ratio of 1:20 to the above reaction mixture. The antibody-HRPO was then dialyzed
against 6 L of 10 mM PBS, pH 7.4, at 4°C for at least 6 hours. Horse serum
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albumin was added to the sample to a final concentration of 10 mg/mL and
dialyzed once more in 6 L of 10 mM PBS, pH 7.4, at 4°C for at least 6 hours.
The antibody-HRPO was placed at 4°C for short term and -20°C for long term
storage.
j. Isotyping of antibodies
Each antibody was tested with Sigma ImmunoType Mouse Monoclonal
Antibody Isotyping Kit, stock No. ISO-1 according to the manufacturer’s
procedure. Two mL of antibody in a concentration of 1 jug/mL were used.
3. Assay conditions
a.

Well coating studies
(1)

CHA preparation studies

Into a 15 x 150 mm test tube, 1.6 g o f CHA and 0.16 g of NaN02 were
placed in an ice water bath. To the CHA and NaN02 mixture, 5 mL of ice cold
concentrated nitric acid were added. The top o f the test tube was sealed with
parafilm to trap the N02 that was produced. The mixture was maintained at 4°C
and stirred until all of the solid CHA was dissolved. One mL aliquots of the
mixture were taken at 8, 12, 24, 36, 42, and 48 hr. To the 1 mL aliquots, 8 mL
of ether were added to precipitate the CHA. The tube was centrifuged for 5 min at
100 xg, and the supernatant was removed. The precipitate was washed again with
4 mL of ether then centrifuged, and the supernatant removed. The precipitate was
allowed to air dry.127

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

51

Each of the oxidized CHA samples was analyzed by infirared analysis on a
Nicolet 5PC FT-DR Spectrometer.
(2)

CHA:BSA coupling studies

From the 36 hr oxidized CHA sample, a stock solution of 10 mg/mL
deionized water was made. The CHA was activated by adding 0.1 M each of EDC
and NHS in deionized water to 2.4 x 10'3M of CHA. This was mixed on a rocker
at room temperature for 30 min. BSA diluted in 0.1 M carbonate buffer, pH 8.6,
to a concentration of 1.5 x 10-4 M was conjugated to the activated CHA and
incubated on the rocker for 1 hr at 4°C in 1:1, 1:2, 1:4, and 1:8 ratios. This was
repeated with increased EDC/NHS in the concentration of 0.1 M of each. This
reaction is diagramed in Figure 7. The resulting CHA-BSA was dialyzed overnight
in 6 L of 50 mM Tris buffer pH 8.5 with 2 changes o f the buffer.
Tenfold dilutions were made of the CHA-BSA with the coating solution
starting at 1 mg/mL. Two hundred /xL aliquots were added to each well. The wells
were incubated overnight at room temperature in a moist chamber.128129
b.

Washing studies

Deionized water; 10 mM PBS, pH 7.4; and 10 mM PBS, pH 7.4, with
0.1 % Tween (PBS-Tween) were chosen as possible washing solutions. Rinsing
patterns performed were 3/3, 5/5, 7/7 of each of the washing solutions followed
by deionized water. Rinses were performed after well coating, blocking, sample
incubation and antibody incubation. The wells were completely filled with the
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Figure 7
Reaction of coupling CHA to BSA
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rinsing agent, then emptied, and after the final rinse were allowed to air dry in
front of a fan for 10 min.128
c.

Blocking studies

The wells were filled with 300 /*L of blocking agent and incubated in a
moist chamber. Blocking agents investigated were BSA, OVA, and skim milk in
coating solution at the following concentrations: 0.3%, 0.5%, 1%, 3%, and 5%.
Incubation was performed at room temperature and 37°C for 30, 45, 60, 90, and
120 min.128
d.

Sample studies
(1)

Sample diluent study

Samples were diluted with 10 mM PBS, pH 7.4, 10 mM PBS, pH 7.4, with
8 mmol/L CaCl2, and 10 mM PBS, pH 7.4, with 0.1 % skim milk . Each sample
was serially diluted twofold with the diluent.128
(2)

Sample size study

Two control sera (normal and abnormal) were serially diluted with 10 mM
PBS, pH 7.4, with 0.1 % skim milk (PBS-SM) and tested with the cross reacting
2PC12-HRPO antibody.
(3)

Sample incubation study

Blanks (PBS-SM) and samples were incubated in a moist chamber at room
temperature and 37°C for 30, 45, 60, 90, and 120 min.
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e. Antibody-HRPO incubation study
The HRPO-conjugated antibody was diluted with 10 mM PBS, pH 7.4, and
incubated in a moist chamber at room temperature and 37°C for 30, 45, 60, 90
and 120 min.
f. Indicator system studies
The substrate solution (solution A) was added proportionally to the well
coating as established previously in this laboratory. The chromogen solution
(solution B) was of equal volume to the substrate, and the 2 N H2S04 was half
volume to the previous two solutions. The color development was allowed to react
for 5, 10, 15 and 20 min with serial dilutions of p-amylase and 2PC2-HRPO;
likewise, with the s-amylase and 2S2F7-HRPO.
4.

Studies of the performance characteristics of the enzyme
immunoassay
a.

Linearity studies

The standards (p-amylase and s-amylase) were added to human serum with
a predetermined amylase level of less than 10 U/L. Each standard was made with
the PBS-SM by twofold dilutions starting with a concentration of 1000 U /L of the
respective isoamylase. These were tested with the appropriate HRPO-antibody.
b.

Limit of detection studies

Twenty blanks were tested with 2PC2-HRPO and 2S2F7-HRPO.
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c.

Precision studies

Twenty determinations of commercially prepared normal pooled serum
were determined with 2PC2-HRPO and 2S2F7-HRPG. Twenty assays using
commercially prepared abnormal pooled serum were also performed with the two
antibodies.
d.

Cross reaction studies

The standards of p-amylase and s-amylase were each tested with the
reciprocal antibody, p-amylase with 2S2F7-HRPO and s-amylase with 2PC2HRPO.
5.

Validation studies of human sera
a.

Enzyme immunoassay

Twenty patient samples, normal control, and abnormal control were
analyzed on Immulon 1 wells previously coated with 20 pg/vjtH CHA:BSA that
had been blocked with PBS-SM for 45 min at 37°C. The samples were diluted 1:5
with PBS-SM, and 200 pL were added to each well. These were incubated at
room temperature for 60 min. They were then washed seven times with 10 mM
PBS, pH 7.4, with 0.1 % Tween followed by seven times with deionized water.
The samples were incubated for 45 min at 37°C with 200 pL of each of the two
antibodies, 2PC2-HRPO and 2S2F7-HRPO, that had been diluted to 1:600 and
1:700 respectively. The wells were again washed, and the two color developing
solutions, A and B, were added. When a blue color developed, the color reaction
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was stopped with the addition of 2 N H2S04. The resulting yellow color was read
on the microplate reader at 450 nm.
b.

Total amylase

Total amylase determination of the patients samples were performed on a
Beckman CX7 which measured the amount of NADH produced.
c.

Electrophoresis

Gloves were worn to prevent any contamination. The number of
applications of the sample onto the cellulose acetate strip was the equivalent of one
application of a sample of an amylase of 500 U/L. This was made about 1.5 cm
from the cathode end of the plate. Tris and barbital buffers were kept refrigerated
then put into the anode and cathode chambers respectively. Electrophoresis was
performed at 3 mA for 1.5 hours with the chamber in an ice bath. After
electrophoresis, the strip was put into a closed chamber with one drop of water
between the cellulose acetate and the glass plates to ensure that it lay perfectly flat.
A Phadebas Amylase test tablet diluted with 3 mL of 8 mmol/L CaCL was poured
onto the electrophoresis plate and incubated at 40°C for 1.5 hours. After
incubation, the plate was quickly washed under cold tap water, then put into
methanol for 5 min to fix the blue bands to the cellulose acetate matrix, and then
cleared in 30% cyclohexane in absolute ethanol for one min. The plate was dried
in a warm oven for approximately 3 min. The strip was scanned at 595 nm, and
the percentages of p-amylase and s-amylase were computed.22130
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Chapter m
RESULTS
A. Preparation of antigens
Pancreatic amylase is unavailable commercially. A pancreas was
homogenized and p-amylase was purified by affinity chromatography using CHASepharose. The amylase was eluted with a solution of 0.8% CHA. This was later
removed by dialysis. As seen in Table 1, not all of the amylase was totally
extracted, still a large amount of p-amylase was obtained with a 58.8% yield from
the original 100.65 grams of pancreatic tissue.
B. Production of antibodies
1. Im m unization of mice

The immunization of the first p-amylase immunized mouse was particularly
long due to the fact that NS1 cells were not available until the 17th week. Two
mice were immunized with s-amylase. The hybridoma clone maintained from the
first s-amylase mouse proved to produce too low of an antibody titer to be useful.
The second s-amylase immunized mouse was maintained with boosters and was
later utilized for cell fusion. However, due to a fungal infection, both p-amylase
and s-amylase cell lines were lost from the fusions of the first p-amylase mouse
and the second s-amylase mouse. Two more pairs of mice were immunized with pamylase and s-amylase. The second p-amylase mouse gave rise to the cell line that
was ultimately used for testing. The cell fusion from the third s-amylase mouse

57
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Table 1. Summary of pancreatic amylase extraction and purification

Sample

original

final

protein

volume
mL

volume

mg/mL

amylase
Units/dL

mL

protein

total
amylase

specific
activity

mg

U

Units/mg

total

yield

purification

%

folds

protein
homogcnatc

425

409

@ 100

44100

40900

1803690

441

0
#1 CHA

21

5.5

.338

930

1.9

5115

2692

0.03

6

#2 CHA

54

41

.653

85000

268

3485000

130037

19.3

295

28

.653

86000

18.3

2408000

131585

13.4

298

50

.22

41500

11

207500

188636

11.5

428

13.5

.258

42000

3.5

567000

162931

3.1

369

48

.266

43400

12.8

2083200

162750

11.5

369

2nd extract
#2
#3 CHA

144

2nd extract
#3
#4 CHA

190

NOTES:
no 3rd extract performed on §2 and #3
no 2nd extract performed on #4; had enough p-amylase; therefore, did not continue.
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resulted in poor results due to the MC-IMDM having aggregates of media. The
alternate mouse was boosted and used for cell fusion. The summary of the
immunizations are shown in Table 2.
2.

Titer determinations

All of the mice used exhibited a significant titer at 13 days. The continued
immunization was due to other factors. The titers of P2 and P3 mouse are shown in
Figure 8. The P2 mouse gave rise to the cell line used for testing (2PC2). The cells
from the P3 mouse were never used. The titers of S3 and S4 mice are shown in
Figure 9; mouse S4 gave rise to cell line 2S2F7 which was used in testing.
3. Cell fusions
The number of clones produced from the six cell fusions varied from 12 to
468. The ideal number to work with was approximately 100. Greater than this
number of cells becomes unmanageable to maintain. Clone picking was usually
performed only once. The one fusion that yielded 468 clones necessitated picking half
of the clones one day and the remaining plates of clones the second day. Since clones
that appeared later were the result of slower growing cell lines and were more likely
to be contaminated from any cell(s) left from the initial clone picking, clones that
grew later were not picked. Clones that were initially positive were screened later
since hybridoma cells are unstable. Clones that were still viable and positive for the
specific antibody decreased to approximately one fourth the original number. The
summary of clone selections are shown in Table 2. Two cell lines that were positive
for one amylase antigen and negative for the other were maintained (2PE10 and
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Table 2 . Sum m ary o f cell fusions
boosters
(days
from
spleen
injection)

titer &
fusion
(days
from
spleen
injection)

clone
picking
(days
from
fusion)

A Of

PI

12d, 13d,
& every
2-3 weeks
thereafter

17 weeks

12, 13

468

SI

11,13

15

11

S2

12,28,42,
56,84

86

10

P2

12,13

15

10

77

S3

12,13,

15

10

12
(*4)

S4

12,13,28

30

12

212

Ag

clones
picked

transfer
(days
from
clone
picking)

Hot

14

336

clones
trans
ferred

Ab
screen
(days
from
clone
picking)

+
and
growth

24
27
36
44

213

48

7
19

48
6-P

6

84

24

20
(*3 )

3,4,5,6

54

12

30
10-S

4,6,8

91

18,28

S3

2nd Ab
screen
(days
from
clone
picking)

+
and
growth

51

127
(*1 )

10
(*2 )

22

15
5-S

35

33
5-P

*1 froze 24 best- lost in freezing technique; worked with 6 best-lost to fungus contaminate of
media
*2 too low o f antibody production
*3 lost to fungus contaminate o f media (same time as PI cells)
*4 fusion media had aggregates o f hard media, too hard to pick clones

Figure 8
Titer assay of anti-p-amylase by solid-phase enzyme immunoassay on microwell
immobilization. Assay run in duplicate.
■ : mouse 1; Y=0.544-0.0812xlog(X), r=0.946
• : mouse 2; Y=0.558-0.079xlog(X), r=0.984

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

61

D ilu tio n

(fo ld s )

o
o

o

(N

o

o

o

o

o

(ran 0 £ t) soneqiosqy

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 9
Titer assay of anti-s-amylase by solid-phase enzyme immunoassay on microwell
immobilization. Assay run in duplicate.
■ : mouse 1; Y=1.409-0.222xlog(X), r=0.994
• : mouse 2; Y=1.116-0.169xlog(X), r =0.962
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2PC2 for p-amylase; 2S2E4 and 2S2F7 for s-amylase). Two other cell lines (2PC12
and 2S1A7) that were cross reactive to both p- and s-amylase were also maintained to
do the initial testing of the enzyme immunoassays.
4.

Production of antibodies in vitro

As the hybridomas were grown to sufficient number for injection into the
mouse to produce ascites fluid, the media that was removed and replaced with fresh
media. The media that was removed was saved, stored at -20°C, and later purified to
determine if a significant amount of antibody could be obtained by the in vitro
cultivation of the cells. The amount varied from 1.4 /zg/mL to 5.7 /zg/mL of complete
media. Two cell lines were also grown in Hybridoma Serum Free Media by Gibco
and yielded 0 /zg/mL and 5.8 /xg/mL for 2PE10 and 2PC2, respectively. In vitro
antibody production is summarized in Table 3.
5.

Production of antibodies in ascites fluid

Ascites fluid production varied from 8 to 26 days from the intraperitoneal
injection of the hybridoma cells with an average of 13 days. The total volume
collected ranged from 3 mL to 17.2 mL. This figure reflects the amount collected not
the total volume produced since some of the ascites fluid was lost during the tap. The
average amount of fluid produced was 5.6 mL and 7.6 mL by priming with pristane
and Incomplete Freund’s Adjuvant, respectively. The average amount of antibody
produced was 0.56 grams/mL of ascites fluid produced. The summary of all antibody
production is in Table 3.
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Table 3. Summary of antibody production
Cell
line

Source

Time from
I.P. cell
injection to
tap-volumc

total
liquid
collected

days-mL

antibody
collected

volume

Yield
liquid
collected

jtg/mL

mL

grams

g/mL

mL
2PE10

2PC2

2S1A7

CM

130

368

@2

7.4xl03

5.7x10*

SF

85

0

@5

0

0

Pr

14-3:16-3

6

886

@5

4.43

0.7383

IF

14-4

3

331

@5

1.32

0.44

CM

120

94

6.8

6.4x10’

5.3x10*

SF

43

46

5.5

2.5x10’

5.8x10*

Pr

11-3.5:13-3.5

7

774

5

3.87

0.5529

IF

8-4.5:9-1.5

5

499

@ 6.5

3.2

0.644

IF

8-4.3:110.5:12-0.5

5

85

50

@5

2.5x10’

2.9x10*

6

688

@5

3.44

0.5733

50

56

@5

2.8x10’

5.6x10*

651

@5

3.26

0.4657

0

0

CM
Pr

2PC12

2S2F7

2S2E4

9-4.5:11-2.8

CM
Pr

9-4.5:11-4

7

IF

12-4:14-4.3:
16-4.5:18-4.4

17.2

CM

40

0
399

@5

2.0

0.50

65

18

@5

9.0x10’

1.4x10*

3.5

383

@5

1.92

0.549

Pr

17-2.6:19-3.3

4

IF

18-1:21-2.5:
24-1:26-3.3:
27-1

7.8

CM
Pr

26-1.3:28-2.2

abbreviations: (CM) complete media,
(SF) serum free media,
(Pr) ascites fluid from pristane primer,
(IF) ascites fluid from Incomplete Freund’s Adjuvant primer,
(@) approximately
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6.

Purification of antibodies

The media in which the hybridoma cells were grown and the ascites fluid were
both purified by affinity chromatography with Protein A-Sepharose using a citrate
buffer of pH 3.0. The elutions of 2PC2 and 2S2F7 are seen in Figures 10 and 11,
respectively.
7. Isotyping of antibodies
All three antibodies (2PC2, 2S2F7 and 2PC12) were determined to be IgG2b
by the Sigma ImmunoType Mouse Monoclonal Antibody Isotyping Kit.
C.

Assay conditions
1.

Well coating studies

Due to cycloheptaamylose’s circular structure of seven glucose units, as seen
in Figure 12, it acts as an inhibitor of amylase. In order to coat the microwells with
cycloheptaamylose it was necessary to attach it to a protein. This was accomplished
by first oxidizing at least one of the hydroxyl groups to a carboxyl group and then
connecting it to the protein by an amide linkage. The circular structure of
cycloheptaamylose also had to be maintained to insure that it remained an inhibitor of
amylase and did not instead become a substrate for amylase. The results of the
oxidation of cycloheptaamylose at 8, 12, 24, 36, 42, 48 and 84 hr are shown by the
graphs of the infrared analysis in Figures 13 and 14. The appearance of an additional
peak at 1750 wave numbers starts to appear at 8 hr. It becomes equal in length to the
peak at 1650 at 36 hours. This concurs with the formation of a carboxyl group, with
the peak at 1650 due to the presence of the carbonyl group in a semiacetyl formation.
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Figure 10
The elution profile of anti-p-amylase from protein A sepharose chromatography
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Figure 11
T h e e lu tio n p r o f ile o f a n ti-s -a m y la s e fr o m p r o te in A s e p h a ro s e c h r o m a to g r a p h
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Figure 13
In f r a r e d a n a ly s is o f th e o x id a tio n o f c y c lo h e p ta a m y lo s e
A. 0 hours, B. 8 hours, C. 12 hours, and D. 24 hours
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Figure 14
Infrared analysis of the oxidation of cycloheptaamylose
A. 36 hours, B. 42 hours, C. 48 hours, and D. 84 hours
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The peak at 1150 concurs with the ether linkage that results in the ring structure of
cycloheptaamylose. When the oxidation was allowed to go for 84 hr, the peak at 1650
began to deteriorate. Oxidation time was chosen to be 36 hr since the two peaks due
to carbonyl and carboxyl groups were equal in length, and it was only necessary to
oxidize one hydroxyl group on cycloheptaamylose.
Of the ratios 1:1, 1:2, 1:4, and 1:8 of BSA to CHA, the highest reacting ratio
was 1:1, as seen in Figure 15. Since the absorbance of all of the ratios was low, a
mean of 0.156, further studies were performed to rectify this.
Activation of the carboxyl group was undertaken with carbodiimide by the
formation of an O-acylurea. However, in an aqueous media this intermediary is
subject to hydrolysis. The presence of N-hydroxy-succinimide (NHS) results h the
formation of an active ester that is more hydrolysis resistant.128129 By increasing the
concentration of EDC and NHS from 1 mM to 0.1 M, the readings were increased
from a mean of 0.156 to 0.565. The best ratio of BSA to CHA was chosen to be 1:1
at a concentration of 20 jig/well since this was the only ratio with a positive slope.
The results are shown in Figure 16.
2.

Washing studies

Three washing agents were tested: deionized water, 10 mM PBS, pH 7.4, with
and without 0.1 % Tween. Each of these was followed by an equal number of
washings with deionized water. Figure 17 shows that, washing 7 times PBS-Tween
followed by 7 times with deionized water gave the greatest difference between the
sample with the antigen and the blank.
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Figure 15
Optimization of coupling oxidized cycloheptaamylose to bovine serum albumin
with 1 mM aqueous l-ethyI-3-(3-dimethylaminopropyl)carbodiimide and
iV-hydroxysuccinimide for assay in solid-phase enzyme immunoassay on microwell
immobilization. Assay run twice.
■ : 1BSA.-1CHA; Y = 0 .176+6.7xlO'5(X), r=0.288
• : 1BSA:2CHA; Y=0.156+2.0xl(T,(X), r=0.451
♦ : 1BSA:4CHA; Y=0.143+2.0xl0J'(X), r=0.534
a : 1BSA:8CHA; Y=0.136-9.2x 10'5(X), r=0.253
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Figure 16
Optimization of coupling oxidized cycloheptaamylose to bovine serum albumin
with 0.1 M aqueous l-ethyl-3-(3-dimethyIaminopropyl)carbodiimideand
jV-hydroxysuccinimide for assay in solid-phase enzyme immunoassay on microwell
immobilization. Assay run twice.
■ : 1BSA:1CHA; Y=0.571+2.0xl0J‘(X), r=0.266
• : 1BSA:2CHA; Y=0.568-2.0xl0-3(X), r=0.604
♦ : 1BSA:4CHA; Y=0.625-6.0xlOJ,(X), r=0.793
a : 1BSA:8CHA; Y=0.581-4.9xl0'5(X), r=0.044
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Figure 17
Washing study on solid-phase enzyme immunoassay on microwell immobilization.
Assay run twice.
Washing agent on samples:
■ : deionized water; Y=0.307-1.6xlO'2(X), r=0.459
• : 10 mM PBS, pH 7.4; Y=0.267-2.0xlO-3(X), r=0.449
♦ : 10 mM PBS, pH 7.4, with 0.1% Tween;
Y=-0.100+8.4x 10'2(X), r =0.999
Washing agent on blanks:
□ : deionized water; Y=0.103+4.2xl0'2(X), r=0.469
0 : 10 mM PBS, pH 7.4; Y=0.262-1.8xl0-2(X), r=0.554
0 : 10 mM PBS, pH 7.4, with 0.1% Tween; Y=0.138+0.0(X), r=0.999
Net difference of sample minus blank:
i:i: deionized water; Y=-0.112+3.3xl0'2(X), r=0.95
gg: 10 mM PBS, pH 7.4; Y=-0.003+1.6xl0'2(X), r=0.686
10 mM PBS, pH 7.4, with 0.1% Tween;
Y=-0.111 +5.0xl0'2(X), r=0.999
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3.

Blocking studies

The three blocking agents tested were BSA, OVA, and skim milk in coating
solution at the following concentrations: 0.3%, 0.5%, 1%, 3%, and 5%. The results
are shown in Figure 18. BSA and skim milk gave the greatest difference between the
sample with the antigen and the blank with BSA being slightly better. OVA appeared
to inhibit the activity of the antigen since little difference was observed between the
sample and the blank. Since both 0.5% and 3% gave the best net difference between
the sample and the blank, they were further tested at room temperature and 37°C.
The results are in Figures 19-22. Of these testings, 0.5% BSA in coating solution for
45 min at 37°C was chosen for blocking the unbound spaces on the polystyrene
surface.
4.

Sample studies
a.

Sample diluent study

The diluents investigated consisted of 10 mM PBS, pH 7.4; PBS-SM; and 10
mM PBS, pH 7.4, with 8 mmol/L CaCl2. Although chloride ions are necessary for
amylase activity, and calcium ions are necessary for the structural

integrity of the

enzyme,4 protein appears to also be necessary to maintain the binding conditions of
amylase to the inhibitor CHA. Figure 23 shows that PBS-SM was the best diluent.
b.

Sample size study

The abnormal control sera used to

test the diluent, as seen in Figure 23,

showed lower activity undiluted than when diluted 1:2 or 1:4. The 1:4 dilution in fact
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Figure 18
Study of dilutions of blocking agents on solid-phase enzyme immunoassay on
microwell immobilization. Assay run at room temperature twice.
Blocking agent with samples:
■ : 10 mM PBS, pH 7.4, with BSA;
• : 10 mM PBS, pH 7.4, with 0.1% skim milk;
♦ : 10 mM PBS, pH 7.4, with OVA
Blocking agent with blanks:
□ : 10 mM PBS, pH 7.4, with BSA;
O: 10 mM PBS, pH 7.4, with 0.1% skim milk;
0 : 10 mM PBS, pH 7.4, with OVA
Net difference of sample minus blank:
I::: 10 mM PBS, pH 7.4, with BSA;
$|$: 10 mM PBS, pH 7.4, with 0.1% skim milk
£ : 10 mM PBS, pH 7.4, with OVA
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Figure 19
Blocking incubation study of 0.5% bovine serum albumin at room temperature
on solid-phase enzyme immunoassay on microwell immobilization.
Assay run twice.
■ : sample; □ : blank;
sample - blank
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Figure 20
Blocking incubation study of 0.5% bovine serum albumin at 37°C on solid-phase
enzyme immunoassay on microwell immobilization. Assay run twice.
■ : sample; □ : blank; $j$: sample - blank
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Figure 21
Blocking incubation study of 3% bovine serum albumin at room temperature on
solid-phase enzyme immunoassay on microwell immobilization. Assay run twice.
■ : sample; □ : blank;
sample - blank
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Figure 22
Blocking incubation study of 3% bovine serum albumin at 37° C on solid-phase
enzyme immunoassay on microwell immobilization. Assay run twice.
■ : sample; □ : blank;
sample - blank
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Figure 23
Sample diluent study on solid-phase enzyme immunoassay on microwell.
Assay run twice.
Diluents: ■ : 10 mM PBS, pH 7.4;
Y=0.587+2.3‘5(X), r=0.074
• : 10 mM PBS, pH 7.4 with 8 mM CaCl2;
Y=0.572-2.1xl04(X), r=0.371
♦ : 10 mM PBS, pH 7.4 with 0.1% skim milk;
on data points 1-85: Y=0.246+4.3xl0'3(X), r=0.926
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showing the highest absorbance. The fact that the activity increases with a smaller
sample size was confirmed by testing twofold dilutions of the normal control sera
along with the abnormal control sera, seen in Figure 24. From these results the
sample size was reduced to 40 /tL instead of 200 /iL/well. A 1:5 dilution of each
sample was made with the PBS-SM (40 piL sample plus 160 ixL PBS-SM) when
performing the assay.
c.

Sample incubation study

Samples of normal control serum and blanks of the diluent were incubated at
room temperature for 30, 45, 60, 90, and 120 min. These results, plus the net
difference between the sample and blank, are shown in Figure 25. This study was
also performed at 37°C, and the results are illustrated in Figure 26. Room
temperature provided the best readings with a 60 min incubation determined as the
best incubation time.
5.

Antibody-HRPO studies

The HRPO conjugated antibodies (2PC12, 2PC2, and 2S2F7) were serially
diluted with 10 mM PBS, pH 7.4, and incubated in a moist chamber at room
temperature and 37°C for 30, 45, 60, 90 and 120 min. The results of the serial
dilutions of the HRPO-antibodies are seen in Figures 27-29. From these 2PC12 was
diluted 1:750 and used for testing the assay procedure. A 1:600 dilution was made for
2PC2, and a 1:700 dilution was made for 2S2F7. The results of incubation times of
30, 45, 60, 90 and 120 min at room temperature are shown in Figure 30. Figure 31
shows the results of the 37°C incubation temperature at the same incubation times.
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Figure 24
Sample size study on solid-phase enzyme immunoassay on microwell.
Assay run twice.
■ : normal control; Y=0.797-2.1xl0'3(X), r=0.901
• : abnormal control; on points 21-85: Y=0.655 +3.0xl0‘3(X), r=0.992
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Figure 25
Sample incubation study at room temperature on solid-phase enzyme
immunoassay on microwell immobilization. Assay run twice.
■ : sample; □ : blank; $$: sample - blank
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Figure 26
Sample incubation study at 37° C on solid-phase enzyme immunoassay on
microwell immobilization. Assay run twice.
■ : sample; □: blank;
sample - blank
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Figure 27
Antibody dilution study of cross reacting anti-p&s-amylase-HRPO (2PC12) on
solid-phase enzyme immunoassay on microwell immobilization.
Assay run in duplicate.
■ : sample; Y=0.852+1.0xl0J'(X), r=0.847
□ : blank; Y=0.570-8.7xl0-5(X), r=0.845
sample - blank;
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Figure 28
Antibody dilution study of anti-p-amylase-HRPO (2PC2) on solid-phase enzyme
immunoassay on microwell immobilization. Assay run in duplicate.
■ : sample; Y=1.136-8.9xl04(X), r=0.940
□ : blank; Y=0.836-7.6xl0^(X), r=0.860
3$: sample - blank
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Figure 29
Antibody dilution study of anti-s-amylase-HRPO (2S2F7) on solid-phase enzyme
immunoassay on microwell immobilization. Assay run in duplicate.
■ : sample; Y=1.127-5.5xl04(X), r=0.827
□ : blank; Y=0.470-1.5xl04(X), r=0.450
sample - blank
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Figure 30
Antibody incubation study at room temperature on solid-phase enzyme
immunoassay on microwell immobilization. Assay run twice.
■ : sample; □ : blank; $$■: sample - blank
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Figure 31
Antibody incubation study of antibody at 37°C on solid-phase enzyme
immunoassay on microwell immobilization. Assay run twice.
■ : sample; □ : blank;
sample - blank
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The antibody appeared to bind better at 37°C than room temperature; therefore, a 45
min incubation at 37°C was selected as the best incubation for the antibody-HRPO.
6.

Indicator system studies

The results of solution A and B incubation at 5, 10, 15 and 20 min with serial
dilutions of p-amylase and 2PC2-HRPO are shown in Figure 32. The results of
incubation with s-amylase and 2S2F7-HRPO are shown in Figure 33. Color
development was best between 15 and 20 min.
D.

Study of the performance characteristics of the enzyme immunoassay
1.

Linearity studies

The assay procedure that was employed in testing for p-amylase and s-amylase
is summarized in Table 4. The results of the serial dilution of p-amylase and 2PC2HRPO are seen in Figure 34. Pancreatic amylase determinations were linear from 8
U/L up to the 1000 U/L tested. Salivary amylase determinations were linear from 16
U/L to the 1000 U/L tested. The linearity of 2S2F7 are shown in Figure 35.
2.

Limit of detection studies

Twenty blanks were run simultaneously with standards for p-amylase and samylase. The standard deviation calculated for p-amylase was 0.064 and for s-amylase
was 0.047. Following the recommendation of the International Federation of Clinical
Chemistry (IFCC), the limits of detection equal 2.6 x S.D., which are 0.166 and
0.122 for p-amylase and s-amylase, respectively. From the standard curve which was
run in the same assay with the blanks, the limits of detection were determined to be 8
U/L for p-amylase and 16 U/L for s-amylase.
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Figure 32
Color development time study of p-amylase solid-phase enzyme immunoassay on
microwell immobilization. Assay run twice.
Incubation times:
■ : 5 min; Y=0.216+8.4xl0^(X), r=0.941
• : 10 min; Y =0.428+1.6xlO'3(X), r=0.912
♦ : 15 min; Y=0.535+2.1xl0'3(X), r=0.980
a : 20 min; Y=0.603 +2.7xl0'3(X), r=0.987
slope vs time: Y=3.5xlO'5+3.3xlOJ‘(X), r=0.932
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Figure 33
Color development time study of s-amylase solid-phase enzyme immunoassay on
microwell immobilization. Assay run twice.
Incubation times:
■ : 5 min; Y = 0 .2 7 7 + l.lxl0 ‘3(X), r=0.946
• : 10 min; Y=0.341+3.2xl0‘3(X), r=0.979
♦ : 15 min; Y=0.383+3.3xl0‘3(X), r=0.947
a : 20 min; Y=0.583+4.9xl0'3(X), r=0.910
slope vs time: Y=2.5xlO'4+2.3xlO'4(X), r=0.953
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Table 4. Summary of the assay conditions for enzyme immunoassay
for p-amylase and s-amylase determination

washing

substance

time

PBS Tween

7
times

followed
by:
DI

temperature

concentration

amount

10 mM
pH 7.4
-0.1%

400 fiL

/
7
times

well coating
ofCHA

CHA:BSA

5-24
hr

room
temperature

20 /ig/well

200 fiL

blocking

BSA in
coating
solution

45
min

37°C

0.5%

300 fiL

antigen

antigen

60
min

room
temperature

antigen
diluent

skim milk
in PBS

antibodyHRPO

antibody in
diluent

antibody
diluent

PBS

color
development

solution A
solution B
h ,so4

45
min

37°C

40 liL
0.1% in
10 mM
pH 7.4

160 /aL

1/600
2PC2-HRPO
1/700
2S2F7-HRPO

200/iL

10 mM
pH 7.4
15-20 room
min
temperature
2N

100 /iL
100 /iL
50jiL
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Figure 34
Linearity of anti-p-amylase-HRPO (2PC2) on solid-phase enzyme immunoassay
on microwell immobilization. Assay run three times.
Y=0.181 +0.3661og(X), r=0.972
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Figure 35
Linearity of anti-s-amylase-HRPO (2S2F7) on solid-phase enzyme immunoassay
on microwell immobilization. Assay run three times.
Y=-0.092 +0.570Iog(X), r=0.933
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3.

Precision studies

Twenty replicates of commercially prepared pooled normal serum and
abnormal serum were assayed in the same experiment for p-amylase and s-amylase. A
summary of the statistical analysis of the assays are in Table 5 for p-amylase and
Table 6 for s-amylase. The coefficient of variation (C.V.%) for p-amylase normal
serum was 7.79%, and 6.28% for abnormal sera. For s-amylase the C.V.% was
9.42% and 9.29% for normal and abnormal sera, respectively.
4.

Cross reactivity studies

Initial screening of 2PC2 showed an absorbance reading of 0.454 against a
blank of complete media with p-amylase precoated on the wells at a
concentration of 1 /zg/mL and 0.006 against a blank of complete media with samylase precoated on the wells at a concentration of 1 /zg/mL. Original screening of
2S2F7 showed an absorbance reading of 0.404 against a blank of complete media with
s-amylase precoated on the wells at a concentration of 1 /zg/mL and 0.032 against a
blank of complete media with p-amylase precoated on the wells at a concentration of
1 uglmL. Later assays using s-amylase and 2PC2 and p-amylase and 2S2F7 resulted
in determinations below the level of detection.
£.

Validation studies
Thirty-two serum patient samples along with a normal control, and abnormal

control were analyzed on Immulon 1 wells previously coated with 20 /zg/well
CHA:BSA that had been blocked with 0.5% BSA in coating solution for 45 min at
37°C. The samples were diluted 1:5 with PBS-SM, and 200 /zL was added to each

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

98

Table 5. Precision studies of p-amylase determination

p-amylase
sample

normal

abnormal

n

20

20

mean

1.253

1.331

max

1.469

1.516

min

1.059

1.182

S.D.

.098

.084

C.V.%

7.79

6.28
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Table 6. Precision studies of s-amylase determination

s-amylase
sample

normal

abnormal

n

20

20

mean

0.866

0.580

max

1.009

0.683

min

0.741

0.489

S.D.

0.082

0.054

c.v.%

9.42

9.29
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well. These were incubated at room temperature for 60 min. They were then washed
seven times with PBS-Tween followed by seven times with deionized water. The
samples were incubated for 45 min at 37°C with 200 pL of each of the two
antibodies, 2PC2-HRPO and 2S2F7-HRPO, that had been diluted to 1:600 and 1:700
respectively. The wells were again washed, and the two color developing solutions, A
and B, were added. When a blue color developed, the color reaction was stopped with
the addition of 2 N H,S04. The resulting yellow color was read on the microplate
reader at 450 nm. The summary of admitting diagnosis, total amylase, cellulose
acetate electrophoresis and E1A for p-amylase and s-amylase are shown in Table 7.
Linear regression of the results gave an intercept of 82.060, a slope of 0.460 and
correlation coefficient of 0.820 for p-amylase; however, samples number 6, 77, and
201 included P3 amylase which is not detected by the EIA. Using just the values of P,
and P2 for the p-amylase value for electrophoresis, the intercept was 21.310, the slope
was 1.152, and the correlation coefficient was 0.920. For s-amylase the intercept
was -1.25, slope 1.15, and correlation coefficient was 0.867.
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Table 7. Comparison of electrophoresis and enzyme immunoassay of p-amylase
and s-amylase on human serum samples

Sample
#

admitting
diagnosis

total
amylase

electro
phoresis
Pamylase

EIA
Pamylase

electro
phoresis
samylase

EIA
samylase

2

gun shot
wound neck

153

15

361

138

175

3

beaten head &
face

524

<10

31

524

656

6

chest pains

4000

3000
(total P)
1200(P,
&P,)
1800 P3

1299

1000

1388

7

auto accident
fractured
pancreas

917

641

1140

276

224

20

mesenteric
ischemia

193

48

51

145

120

22

pancreatitis

157

110

138

47

40

70

35

46

35

76

26
29

shingles
pancreatitis

127

57

248

95

75

34

pneumonia

625

<10

33

625

527

77

coronary
artery disease

165

<10
135 P3

13

<10

<16
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Table 7 Comparison...serum samples (continued)
Sample
#

admitting
diagnosis

total
amylase

electro
phoresis
Pamylase

EIA

102
EIA

Pamylase

electro
phoresis
samylase

samylase

95

pancreatitis

204

126

126

35

582

201

pancreatitis
alcohol

389

331
(total p)

107

58

<16

135
(Pi&Pj)
196 P3
202

gun shot
wound

267

<10

14

267

<16

203

bums

67

27

15

40

29

204

shortness of
breath

97

49

32

49

<16

206

abdominal pain

98

<10

11

98

99

207

transplant

118

<10

9

118

126

208

pain crisis
vasoocclusive

35

25

25

10

<16

209

chest pain

167

117

132

50

243

? M I acute
gout
210

chest pain
? M I acute
gout

356

249

272

109

80

211

pancreatitis

210

158

100

52

34
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Table 7 Comparison...serum samples (continued)
Sample
#

admitting
diagnosis

total
amylase

electro
phoresis
Pamylase

103

Pamylase

electro
phoresis
samylase

EIA
samylase

EIA

213

sepsis renal
failure

210

84

57

126

66

214

pancreatitis
hepatitis?

679

475

474

204

212

57

abdominal pain

94

47

64

47

60

216

flu 3 days

24

12

<8

12

<16

217

leukemia

195

137

30

58

70

218

leukemia

234

129

125

105

80

243

aneurism

162

65

74

97

96

87

pancreatitis?

152

76

53

76

25

219

? M I chest
pain

66

26

32

40

32

224

acute

155

62

265

93

100

cholecystitis
225

stomach pain

75

30

239

45

33

VI

normal
control

80

32

37

48

44

V II

abnormal
control

340

170

129

170

250
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Chapter IV
DISCUSSION
A.

Amylase
1. Purification
Normal pancreatic tissue obtained from autopsy was purified by various other

procedures that included (NH4)2S04 precipitation, acetone and sodium acetate
extraction; however, the procedure outlined in the methodology gave the best
yield.119,120121 The main essential was that all of the extractions had to be performed as
quickly as possible while maintaining the enzyme’s stability in a concentrated solution
of pH 7.0 to 8.0, and stored at 4°C or less.
2.

Amylase standards

The purified p-amylase was stored at -80°C with some smaller aliquots at
-20°C and 4°C. Activity did decrease over the period of a year. The -80°C preserved
the amylase best while 4°C preserved it the least. Dilutions of the enzyme were later
added to human serum with an amylase value of 6 U/L for the establishment of the
standard curves. Storage of the enzyme appears to be better in a higher protein media
than the 10 mM PBS, pH 7.4, buffer. The p-amylase and s-amylase standards were
assayed first in the PBS-SM diluent; however, their activity was not as great as when
they were added to either serum free amylase, serum that had been extracted with
CHA-Sepharose, or serum with an amylase level of less than 10 U/L. The serum with
the amylase level of less than 10 U/L gave the best reactivity for the isoamylases.
Electrophoresis of the p-amylase and s-amylase in 10 mM PBS, pH 7.4, were

104

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

105

performed. The p-amylase sample gave one distinct sharp band. The s-amylase had a
few much smaller peaks on the scan of the cellulose acetate electrophoresis. The samylase was purchased commercially and not subjected to Protein A Sepharose
purification. Of the two assays, s-amylase determinations had a higher detection limit,
a lower correlation coefficient, and the C.V.% for the normal and abnormal control
sera were higher than for p-amylase.
3.

Chemical properties

The chemical properties of amylase afford an unusual opportunity for its
quantification. Its molecular weight of 54,96712enables it to be used as an antigen in
an EIA sandwich assay; thus, it can be used to elicit an antibody response without
having to be attached to a larger protein as a carrier. Hence, the opportunity for
incorporating it into EIA procedures is possible. Pancreatic amylase and s-amylase
differ by 1% in their amino acid sequence.8This difference is only slight but is
sufficient to differentiate the two isozymes by electrophoresis.10 Furthermore,
production of specific monoclonal antibodies against each is becoming more
SUCCeSSful 76.77.112.U3-116.118

Because amylase is an enzyme, its enzymatic reactivity has been utilized for
assay procedures.12,67'69 Additionally, amylase’s binding affords another opportunity
for its determination. Robyt and French demonstrated that the active binding site of
amylase binds a maximum of five glucose units. In addition, binding of the substrate
appears to be polar with the reducing end closest to the catalytic group.131
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B.

Cycloheptaamylose
The substrate/inhibitor binding characteristics of amylase were the basis of the

development of this EIA since cycloheptaamylose is composed of seven glucose units
in a circular structure. It is a perfect inhibitor of amylase, is inexpensive and is
readily available. The unique properties of CHA enabled it to be used not only as the
means of purifying p-amylase but also as a means of developing a unique sandwich
assay. The principle of the assay is based on the CHA-amylase-antibody-HRPO
complex being formed. The patient sample is added to a microwell precoated with
CHA. The amylase (antigen/enzyme) binds to the CHA which is bound to the solid
phase (microwell) during incubation, then later the excess amylase is washed off. The
enzyme labeled antibody is allowed to incubate with the complex, then the excess
labeled antibody is washed off. The indicator system consisting of a substrate and
chromogen is added, and the color develops proportionally to the amount of amylase
in the sample, as demonstrated in Figure 36.
Traditionally, in the heterogeneous noncompetitive enzyme immunoassay or
sandwich assay, an antibody is coated onto the solid phase. The sample with the
antigen is allowed to react, then the excess is washed off. A second antibody which is
labeled with an enzyme attaches to a different site on the antigen. The excess enzyme
labeled antibody is washed off, and the substrate and chromogen are added.
The resulting color reaction from the addition of the substrate and chromogen is
directly proportional to the amount of antigen in the sample.
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Figure 36
Principle of the enzyme immunoassay for p-amylase or s-amylase
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color
development
Antibody-HRPO
amylase
BSA-oxCHA
well
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In order to attach CHA to the microwell it was necessary to couple it to a
protein first. The protein, in turn, was then adsorbed on to the surface of the
polystyrene surface of the microwells. It was first necessary to convert at lest one of
the primary alcohols to a carboxylic acid and then, by an amide linkage, to couple it
to the protein. Several means of oxidation of the CHA and its subsequent purification
were attempted. The nitric acid mixture decomposed the DEAE cellulose column
midway through its elution.127 A method to couple the CHA by using sodium
periodate and dioxane to 6-aminohexanoic acid was also attempted. This would
produce a compound which would act as a linker to the protein. This required the
use of size exclusion chromatography utilizing Sephadex G-10-120. Likewise,
coupling it to chloroacetic acid and then OVA and also BSA was also unsuccessful.131
Finally, the oxidation of a primary alcohol to a carboxylic acid was successful using
the sodium nitrite-nitric acid mixture; however, care had to be taken, as the resulting
brown nitrous dioxide gas is rather toxic. The resulting carboxyl group enabled CHA
to be coupled by an amide linkage to BSA by first activating it with carbodiimmide
resulting in an O-acylurea. Essential to this coupling was the presence of the NHS
which helped to prevent the hydrolysis of the activated carboxylate of CHA. The first
attempts at the BSA coupling were unsuccessful until NHS was added in the reaction
mixture at sufficient strength.128The BSA:CHA conjugate was then able to be coated
onto the polystyrene surface of the microwells; thus, the enzymatic function of the
antigen, amylase, resulted in its attachment to the well. The next part of the reaction

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

109

depended on the antigenic properties of amylase with the utilization of the specific
antibody against p-amylase or s-amylase.
C.

Antibody production
1.

Cell fusion

The first cell fusion gave the greatest yield of clones: 468! But this number of
clones was very difficult to maintain for one person. A fusion resulting in 100 clones
is an ideal number. Since newly formed hybridomas are highly unstable, it is
probably a waste of time to screen the clones for positive antibody production for the
first 10 days since some will either cease to be viable or stop antibody production. It
was observed that only one-fourth of the cells from those initially picked remained
viable and produced antibodies specific for the antigen. The maintenance of
hybridomas is particularly tedious. Aseptic technique has to be maintained at all
times. Initially, the incubator was washed with a 2% lysol solution and then rinsed
with ethanol. The water that was kept in the bottom to maintain humidity was
changed weekly. The outside of the flasks were rinsed with 70% ethanol prior to
placing them in the hood for either transfer of cells or the addition of new media.
Gloves were worn and washed with 70% ethanol before handling the flasks. Flasks
were flamed prior to opening and again before entering with a sterile pipette or
pouring. Even with all of these precautions, contamination did occur resulting in the
loss of two cell lines. The fungal infection was the result of the addition of new media
that was contaminated. It is advisable to never change all the cell flasks or wells of a
growing cell line at the same time.
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The initial freezing technique for maintaining cells proved unsuccessful; hence,
the back up lines from the first fusions were lost. Initially, cells were placed at -20°C
for 2 hrs, then -80°C for 4 hrs, then transferred to the gaseous phase of liquid
nitrogen. Later, this was changed to transferring the cells immediately into gaseous
phase of liquid nitrogen. The amount of DMSO was also reduced from 10% to 6%
with 20% FBS in serum free media. Recovery of frozen cells was usually from 50 to
75%.
2.

Ascites fluid production

Initially, ascites fluid production was only minimally successful. Other strains
of mice that were tried were Balb/CJ and a"CFl"; both of these yielded ascites fluid
only in one out of ten attempts. The mouse strain was changed to the Balb/CByJ, and
the concentration and amount of cells injected were increased. It is also essential that
the cells are in the log phase, not in the stationary phase, of growth when they are
injected. Hybridoma cells are rather large and fragile; hence, they were drawn into
the syringe without a needle. A 25 G needle was later placed on the syringe for
injection. When a larger gauge needle was used, the cell solution tended to leak out of
the peritoneal cavity. After the ascites fluid was produced, as was evident by the
swelling of the abdomen of the mouse, it was also possible to recover hybridoma cells
from the peritoneal cavity. The ascites fluid contained both hybridoma cells and
fibroblast which eventually died. The media needed to be changed daily since
contamination was at a greater risk with the ascites fluid due to the collection
technique. Attempts at drawing the ascites fluid from the peritoneal cavity into a
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syringe proved unsatisfactory. Invariably, the intestine or peritoneum would block the
bevel of the needle. The Incomplete Freund’s Adjuvant, which gave slightly higher
volume yield of ascites fluid, required 7-10 days inoculation prior to cell infusion.
This was either advantageous if hybridomas were not in sufficient quantity for
injection or disadvantageous because of the extra time required. Since sufficient
antibody was purified from the pristane primed mice, the two highest ascites fluids
produced were frozen but never extracted to determine the yield of antibody.
D.

Diagnostic groups
The two groups with the highest incidence of acute pancreatitis are those

patients with gallstones and alcoholism.25,26,27 The high incidence association with
gallstones is often the result of the gallstone blocking the ampulla of Vaater, which is
shared by the bile duct in some individuals. Other groups are also predisposed to
producing a pancreatitis such as those individuals suffering from an infarction,
ischemia,39 and cardiopulmonary bypass surgery (which also can have a
hyperamylasemia without a pancreatitis),41 The administration of calcium chloride
appears to be dose related with pancreatic cellular injury.43 This is a curious
phenomena since both calcium and chloride are necessary for amylase activity.
Ironically, surgical procedures in and around the pancreas, such as endoscopic
retrograde pancreatography,51 that are often performed for treatment and/or
diagnosing pancreatitis are known to elevate amylase levels and have also been known
to induce a pancreatitis. The highest levels of amylase, greater than 1000 U/L, are
seen in gallstone related pancreatitis.29
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Increased s-amylase levels frequently associated with cardiac surgery are often
associated with the severity of pleural effusion.44 Total body irradiation also increases
the quantity of serum s-amylase.24
Reduced p-amylase is associated with chronic pancreatitis79 and carcinoma of
the pancreas.66
Renal failure is associated with an increase in both amylase isozymes.46
Trauma to any organ of amylase predominance (parotid gland, submandibular gland
and the pancreas) will cause an increase in the respective amylase levels.
E.

Human serum samples
1.

Sample diluents

Sample diluent was of primary concern in this EIA procedure since the
determination of amylase not only depended on the antigenic properties of amylase
but on its enzymatic properties as well. It is not surprising that chloride ions were
necessary for the enzymatic reactivity of the amylase since this is a well documented
fact.4 However, the necessity of placing the amylase standard in human serum to
optimize the reaction was. Although high concentrations of the protein in human
serum, as was seen in undiluted specimens, reduced the binding of amylase, it was
necessary to optimize the reaction of the standards. This was evident by the increased
activity of the standards in human serum. The patient samples, on the other hand, had
to be diluted with the diluent by at least 1:4. A 1:5 dilution was chosen to reduce the
interference of the serum protein in the reaction. This was advantageous in that the
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sample size was reduced from 200 /zL to 40 /zL, with the remaining 160 /zL being
diluent.
2.

Enzyme immunoassay of human serum samples

The isoamylase EIA, as it was performed on patient samples, was consistent
with the admitting diagnosis of patients with "pancreatitis" that also showed increased
amylase and lipase levels. In one case, the EIA showed an increase that the
electrophoresis did not. Of the admitting diagnoses that were most probable to be
correlated with increased s-amylase values: "beaten head and face", "gun shot wound
neck", and "pneumonia", all showed increased s-amylase by electrophoresis and EIA.
Unrelated admitting diagnoses such as "burns", "aneurism", "leukemia", and "flu"
exhibited normal p-amylase and s-amylase levels by both methods. There were a few
specimens that showed poor correlations. This was probably due to the fact that some
patient samples were kept for a year at 4°C. Their amylase activity did not decrease;
however, when they were tested by the EIA method, very high values were obtained
for either p-amylase and/or s-amylase. This was probably the result of non specific
binding of other serum constituents.
The source of p-amylase for the immunization and enzyme standards for the
EIA procedure was normal pancreatic tissue. This is certainly a good source for
isoamylase P, and P2; however, it does preclude the detection of P3 isoamylase. This
was the case in three of the patient samples. P3 isoamylase determined by cellulose
acetate electrophoresis has a positive efficiency of 93% and a negative efficiency of
100%.81 Thus, the value of incorporating P3 into an immunoassay procedure is worth
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considering. However, it has not been reported that P3 isoamylase is present without
an increased total p-amylase; therefore, the main advantage of measuring P3
isoamylase levels is specificity not sensitivity. Pancreatic amylase levels appears to be
more sensitive to the diagnosis of pancreatitis than total amylase levels. A method for
determining P3 levels would be even more specific for acute pancreatitis.79
3.

Electrophoresis

Electrophoresis procedures which are currently used for determining the levels
of specific isoenzymes for amylase are labor intensive, and only a few specimens can
be analyzed at one time. A typical assay employs two standards and two controls;
therefore, out of an eight sample strip, only four samples can be run at once. The
turn-around-time for the assay is also long. The electrophoresis alone takes 1.5 hrs
plus 1.5 hrs of incubation with the substrate-dye. Then the gels need to be cleared,
dried and scanned. Also, interpretation of the results obtained by electrophoresis is
very subjective. In scanning the strip, the placement on the scanner can greatly
influence the results. Often during the run, the samples do not move in a straight line
but migrated at an angle. It is necessary to visually check the bands to insure that the
scanner is not at an end of one of the bands instead of the middle. The bands have to
be compared manually to the standards in the run to interpret which peak is which
isoenzyme. The scanner does not automatically interpret which peak is which
isoenzyme. The P3 band can be confused with the S, band particularly if the level of
s-amylase is reduced. Thus, marking the results of the scan for the integration of the
percentages of each isoenzyme is, again, a subjective determination. Values of the
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amount of any isoenzyme can easily vary 20%. Scans of the electrophoresis of several
patient’s samples are illustrated in Figure 37.
E.

Summary
Tests that utilize enzymatic activity were the first improvement on the early

colorimetric methods. The introduction of fluorescent methodology offered increased
sensitivity, but they had the problem of contamination and high backgrounds. The
introduction of radioimmunoassays was a major advancement in clinical chemistry in
its sensitivity and specificity. However, these had inherent problems that were not
initially obvious. With increased concern about the environment and safety in the
work place for employees, the use of radioactive isotopes fell into disfavor.
The development of polyclonal antibodies and EIA methods have made the
possibility of detecting nanogram levels of a substance available. Enzyme
immunoassay procedures have advantages over colorimetric test for sensitivity and
specificity. They also have advantages over radioimmunoassays which require special
storage precautions, have limited shelf-lives, and require disposal of radioactive
waste. Many of the enzyme dependent assays have the disadvantage that there are
outside sources of the enzyme in the indicator system. This is the case in tests
employing the NAD+/NADH system. If a suitable blank is not part of the assay
system, the high background can lead to erroneous results. Currently, the use of
monoclonal antibodies adds the advantage of greater specificity. The old problems of
hemolysis, lipemia, and bilirubin interference are not the concern that they once were.
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Figure 37
Electrophoresis of human serum samples
A Patient 26, B patient 208, C Patient 29, D Patient 201
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Amylase determinations have proven to be a sensitive indicator for detecting
pancreatitis. Pancreatic amylase determinations appear at present to be the most
sensitive indicator of pancreatitis.79 The possibility of incorporating a monoclonal
specific for P3 isoamylase is worth pursuing. With the incorporation of EIA specific
for p-amylase, the sensitivity is not only enhanced but specificity is also increased.
Pancreatic amylase and s-amylase determinations have the possibility of being
automated, thus easily incorporated into the clinical laboratory. Initially, the value of
isoamylase EIA determination is in its specificity in detecting pancreatitis; however, it
can also help in distinguishing a pancreatitis from other causes of increased amylase
levels. Pancreatic amylase measurements by EIA becomes particularly advantageous
with the need for a short turn-around-time. This p-amylase EIA method can be used
as a diagnostic test with an assay time length of 2 hours under optimized conditions.
This could probably be shortened to 1 hour with the advantage that it can be
automated. Hospital laboratories do not perform isoamylase determinations as the
electrophoresis method is too costly and time consuming. Instead, they are sent to a
reference laboratory which further increases the turn-around-time. The equipment for
performing automated EIA procedures is already present in most sizeable hospital
laboratories. Therefore, the incorporation of isoamylase measurements by EIA is a
feasible possibility for the near future.
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APPENDIX
SOLUTIONS

Complete medium (100 mL):
deionized water
FBS (HI)
RPMI 1640 with glutamine (10X)
HT (50X)
NaHC03 (7.5%)
P/S (100X)

75
10
1.04
2
2.2
1

mL
mL
g
mL
mL
mL

88
1.04
2.2
0.3
1.0

mL
g
mL
mL
mL

Serum free media (100 mL)
deionized water
RPMI 1640 with glutamine (10X)
NaHCOj (7.5%)
NaOH (1 N)
P/S (100X)

The pH was adjusted on the above two media with 1 N HC1 to 6.8-7.0; then
brought to volume with sterile distilled water. Media was filtered through a
0.22 fxm filter unit into sterile 100 mL bottles and stored in the refrigerator.
When it was needed for use,it was warmed in a 37°C water bath.

2x IMDM (100 mL)
Iscove’s medium powder
NaHC03
a-thioglycerol
P/S (100X)

3.54 g
0.6048 g
2

[iL

4

mL

Methylcellulose
2 g methylcellulose + 50 mL distilled H20; autoclaved for 15 min at 15 psi
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Polyethylene glycol (PEG)
1.5 g PEG is autoclaved for 15 min @ 15 psi; then 1.5 mL serum free
medium was added when PEG was warm.

Solution T (15 mL)
Fetal Bovine Serum
HAT (100X)
LPS (lipopolysaccharide)
(4 mg/mL serum free IMDM)
thymocytes
2X IMDM
distilled water

10
1
0.2

mL
mL
mL

2 x 108
1.4
mL
2.4
mL

Thymocyte suspension
Thymocytes were obtained as previously described and stored in complete
medium at 4°C in a concentration of 1 X 108 cells. For a clone in a 96 well
dish, 250 (iL of thymocyte suspension containing 104 - 10s cells/mL in
complete medium were used. Microwells were fed with 25 ^L/well of the
thymocyte suspension at least once a week for growing clones.

MC-IMDM
Four grams of methylcellulose in 100 mL of sterile distilled water plus 100
mL sterile 2X IMDM. It may be stored at -20°C for up to 6 mo.

Protein A elution buffer
Dissolve 5.46 g citric acid monohydrate (52 mM) and 3.28 g Na2HP04*7H20
(24.5 mM) in deionized water to a final volume of 500 mL. Adjust pH to 3.0
with 1.0 N NH4OH.

Substrate solution
The substrate solution (solution A) contained 2% (w/v) hydrogen peroxide in
0.1 M citric acid and 0.1 M sodium phosphate, pH 5.0. The solution was
stored at 4°C.
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Chromogen solution
The chromogen solution (solution B) was prepared by dissolving 20 mg 3, 3’ ,
5, 5’-tetramethylbenzidine (TMB) completely in 1.0 mL DMSO and then
adding, 10 mL of glycerol, 40 mL methanol and finally bringing it to 100 mL
volume with distilled water to a final concentration of 0.2 mg/mL. The
chromogen solution was stored at 4°C in a brown bottle.

Amylase screening solutions
Stock Substrate Solution
Dissolve 100 mg amylose (50 g/L) in 2 mL of dimethylsulfoxide by stirring at
80°C, in a water bath. Store at 4°C.

Working Substrate Solution
Mix 100 uL stock substrate solution in 4.9 mL 50 mM Tris buffer, pH 8.5.
Make fresh when needed (1 g/L).
Iodine Stock
Dissolve 4 g KI in 50 mL deionized water. Dissolve 100 mg I2. Bring to 100
mL with deionized water. Store in a plastic brown bottle at 4°C

Iodine Working Solution
Mix 20 mL stock iodine solution with 170 mL deionized water. Add 10 mL
glacial acetic acid. Store in a plastic brown bottle at 4°C.
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